**Name of Journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 21064**

**Manuscript Type: TOPIC HIGHLIGHTS**

**2015 Advances in Gastric Cancer**

**Dysregulation of non-coding RNAs in gastric cancer**

Yang Q *et al.* Gastric Cancer and Non-coding RNA

Qing Yang, Ren-Wen Zhang, Peng-Cheng Sui, Hai-Tao He, Lei Ding

**Qing Yang, Ren-Wen Zhang, Peng-Cheng Sui, Hai-Tao He, Lei Ding,** Department of Pathogenobiology, College of Basic Medical Sciences, Jilin University, Changchun 130012, Jilin Province, China

**Author contributions:** Yang Q designed project and performed a critical revision of the paper; Zhang RW, Sui P, He H and Ding L contributed to research and writing of the paper.

**Supported by** National Natural Science Foundation of China, No. 31571443 (to QY); Jilin Provincial Science and Technology Department, No. 20140414031GH and No. 20150101121JC (to QY); Health and Family Planning Commission of Jilin Province, No. 2014Z068 (to QY); and Graduate Innovation Fund of Jilin University, No. 2014031 (to RZ).

**Conflict-of-interest statement:** The authors have no conflict of interest to report.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**correspondence to: Qing Yang, PhD, Professor,** Department of Pathogenobiology, College of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun 130012, Jilin Province, China. yangq@jlu.edu.cn

**Telephone:** +86-431-85619439

**Fax:** +86-431-85619105

**Received:** June 28, 2015

**Peer-review started:** July 2, 2015

**First decision:** July 20, 2015

**Revised:** August 28, 2015

**Accepted:** September 14, 2015

**Article in press:**

**Published online:**

**Abstract**

Gastric cancer (GC) is one of the most common cancers in the world and a significant threat to the health of patients, especially those from China and Japan. The prognosis for patients with late stage GC receiving the standard of care treatment, including surgery, chemotherapy and radiotherapy, remains poor. Developing novel treatment strategies, identifying new molecules for targeted therapy, and devising screening techniques to detect this cancer in its early stages are needed for GC patients. The discovery of non-coding RNAs (ncRNAs), primarily microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), helped to elucidate the mechanisms of tumorigenesis, diagnosis and treatment for GC. Recently, significant research has been conducted on non-coding RNAs and how the regulatory dysfunction of these RNAs impacts the tumorigenesis of GC. In this study, we review papers published in the last five years concerning the dysregulation of non-coding RNAs, especially miRNAs and lncRNAs, in GC. We summarize instances of aberrant expression of the ncRNAs in GC and their effect on survival-related events, including cell cycle regulation, AKT signaling, apoptosis and drug resistance. Additionally, we evaluate how ncRNA dysregulation affects the metastatic process, including the epithelial–mesenchymal transition, stem cells, transcription factor activity, and oncogene and tumor suppressor expression. Lastly, we determine how ncRNAs affect angiogenesis in the microenvironment of GC. We further discuss the use of ncRNAs as potential biomarkers for use in clinical screening, early diagnosis and prognosis of GC. At present, no ideal ncRNAs have been identified as targets for the treatment of GC.

**Key words:** Gastric cancer; Non-coding RNA; Dysregulation; Tumorigenesis; Biomarker

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Gastric cancer (GC) is a significant threat to the health of patients. Non-coding RNAs, primarily microRNAs and long non-coding RNAs, play important roles in gastric tumorigenesis. In this study, we review papers published in the last five years on the dysregulation of non-coding RNAs, especially microRNAs and long non-coding RNAs, in GC. We summarize how aberrant expression of the non-coding RNAs in GC affects cancer cell survival and metastasis, as well as angiogenesis within the tumor microenvironment. We additionally discuss the potential use of non-coding RNAs in the clinic as biomarkers for the diagnosis and prognosis of GC.

Yang Q, Zhang RW, Sui PC, He HT, Ding L. Dysregulation of non-coding RNAs in gastric cancer. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Gastric cancer (GC) is the fourth most common cancer in the world[1] and has high incidence and mortality in Asia, especially in China and Japan. The addition of widespread gastroscopy to normal practice in Japan has resulted in improved early detection rates[2]. In addition to traditional pathogenic pathways that lead to the genesis of GC, *Helicobacter pylori* (*H. pylori*) infection has also been shown to induce gastric tumor growth[3]. Previous studies of the mechanisms leading to GC hypothesized that tumorigenesis was occurring primarily through abnormal protein-protein interactions[4-6], There has been interest in uncovering these underlying mechanisms[7,8]. Recently, significant research has been conducted on non-coding RNAs, including small non-coding RNAs and long non-coding RNAs (lncRNAs)[9-11]. Non-coding RNA regulatory dysfunction plays a significant role in the development of GC.

MicroRNAs (miRNAs) are approximately 22 nucleotides of noncoding single-stranded RNA molecules that are coded by endogenous genes and target specific mRNA molecules by forming miRNA-induced silencing complexes, resulting in mRNA degradation or hindrance of mRNA translation to functional protein. At present, miRNAs have been found to have many biological functions[12-14], including regulation of cell growth and differentiation. Thus, miRNAs play a key role in the life cycle of the cell, and their dysfunction can lead to a diseased state[15-18]. Most miRNAs are highly conserved in the genome and have a high degree of tissue specificity and temporal regulation[19-21]. These properties make miRNAs ideal biomarkers that can be detected for cancer identification. Early detection and accurate monitoring of biomarkers are crucial for treatment and positive prognosis in cancer patients, making biomarker identification particularly significant[22,23]. Recently, cell-free nucleic acids, including a population of miRNA, has been identified in the blood of cancer patients, and their clinical relevance is attracting considerable attention[24] .

LncRNAs are RNA molecules longer than 200 nucleotides that are not translated into protein. They constitute a major, though still poorly characterized, component of the human transcriptome. However, growing evidence suggests that they play an important regulatory role in many cell processes[25-27]. Nonetheless, lncRNAs remain among the least well understood of the RNA transcripts. Though previously dismissed as transcriptional “noise”, several lines of evidence have suggested that lncRNAs are biologically functional[28]. LncRNAs, particularly highly conserved ones, are generally actively regulated and may function predominantly during embryonic development. Most lncRNAs evolved rapidly in terms of sequence and expression levels, but tissue specificity is often conserved[29]. It is becoming increasingly clear that many lncRNAs are deregulated in cancer, and some are functionally tied to mechanisms that may allow them to be important drivers of malignant transformation.

Protein-protein interaction networks are increasingly being employed to characterize cellular processes. These networks will have to be expanded considerably to characterize all of the possible modes of action that can occur. For example, miRNA can silence target genes, and lncRNA in turn can interfere with gene silencing. In contrast, lncRNA interference with target proteins can be influenced by miRNA. For example, lncRNA-RoR is a key competing endogenous RNA that links the network of miRNAs to core transcription factors[30]. Between protein-miRNA interactions, protein-lncRNA interactions, and micRNA-lncRNA interactions, there are many possible and uncharacterized interactions that could become dysfunctional and drive tumor development. Consequently, the development of appropriate biomarkers derived from these non-coding RNAs that reflect an individual’s cancer risk is essential to reduce GC-related mortality.

**DYSREGULATION OF NON-CODING RNAS IN GASTRIC CANCER**

***MiRNAs***

MiRNAs play critical roles in physiological and pathological processes[31-33]. Using miRNA microarray technology, it has been discovered that thousands of miRNAs are dysregulated in GC compared with adjacent tissues; however, only a fraction of these were confirmed through quantitative real-time PCR. Tables 1-3 show the major miRNAs that have been confirmed by quantitative reverse transcription PCR (q-RT PCR) and found to be dysregulated in GC tissues since 2010. Many of these miRNAs were demonstrated to act as tumor promoters or suppressors by regulating the expression level of their target mRNAs in GC cells. However, the mechanisms that control miRNA regulation are as of yet unknown. Below, we have listed some mechanisms linked to altered miRNA expression in GC cells.

Multiple miRNAs were found to be dysregulated in *H. pylori*-positive GC tissues compared with *H. pylori*-negative GC tissues. It was reported that a total of 219 of the 3523 measured miRNAs showed a 2-fold alloeosis (up- or down-regulation) in *H. pylori*-positive GC tissues compared with *H. pylori*-negative GC tissues[34]. Further studies revealed three miRNAs (miR-99b-3p, miR-564, and miR-638) that were significantly up-regulated in three *H. pylori*-positive GC samples, while four miRNAs (miR-204-5p, miR-338-5p, miR-375, and miR-548c-3p) were significantly down-regulated in all eight *H. pylori*-positive GC samples. In addition, the levels of miR-223 and miR-222 were up-regulated while miR-375 and miR-320 were down-regulated in *H. pylori*-infected gastric mucosa[35-38]. MiR-146a was up-regulated in *H. pylori*-infected human gastric epithelial cells and has been shown to decrease the inflammatory response induced by *H. pylori* partially through reducing the level of PTGS2[39]. Further work revealed that miR-146a could enhance apoptosis in GC cells, and there was a positive correlation between miR-146a level and the rate of apoptosis rate in *H. pylori*-positive GC tissues. The mechanism by which these miRNAs become dysregulated is still unclear and requires further investigation, but NF-κB, a key transcription factor in the development of *H. pylori*-induced chronic inflammation may play a critical role in this process. Accordingly, the level of miR-200 was increased in *H. pylori*-infected GC cells driven by a functional NF-κB binding site in the promotor of the miR-200b-200a-429 cluster, which strongly suggests that NF-κB plays an important role in the direct regulation of miR-200 transcription[40]. Increased expression of miR-200 may be a response to the unalterable loss of the epithelial phenotype of GC cells induced by *H. pylori*. MiR-155 was up-regulated by *H. pylori* both *in vitro* and *in vivo*, and this induction was NF-κB dependent[41]. In addition, *H. pylori* could also induce the expression of miR-155 in T cells in a cAMP-Foxp3-dependent manner[42] and in macrophages in a T4SS-dependent manner[43]. MiR-155 was proven to be necessary for Th17/Th1 differentiation and the induction of chronic gastritis in a mouse model infected with *H. pylori*[44]. Furthermore, increased levels of miR-155 suppressed the production of IL-8 induced by *H. pylori* in gastric epithelial cells[41] by regulating the expression of MyD88[45]. IL-6 is a pro-inflammatory cytokine negatively regulated by miR-155 and miR-146b in *H. pylori*(cagA+)-induced gastroduodenal ulcers[46]. Let-7b was found to be involved in the activation of NF-κB in response to *H. pylori* infection induced inflammation and immune responses[47]. Let-7b was down-regulated in *H. pylori*-infected gastric epithelial cell lines and the forced overexpression of let-7b inhibited the activation of NF-κB by suppressing the level of TLR4 in these cells. These results demonstrate that let-7b is a negative regulator of NF-κB and that this may be the reason for let-7b down-regulation in *H. pylori*-infected gastric epithelial cells. The levels of several pro-inflammatory cytokines in *H. pylori* induced chronic inflammation, including IL-1β, IL-6, IL-8, and TNF-α, was found to be correlated with miRNA expression[48]. This evidence suggests the possibility that chronic inflammation mediated by pro-inflammatory cytokines plays a role in regulating the expression of miRNAs in *H. pylori*-infected GC, though the mechanism by which this might occur remains unknown.

Accumulated evidence shows that DNA methylation of miRNA promotor sites is a critical mechanism for miRNA dysregulation in tumors, including GC. Investigation of the methylation frequency of 9 miRNA CpG islands in human gastric samples, including gastritis, GC and normal tissues, revealed that methylation frequency was increased in 5 CpG islands (miR-9-1, miR-9-3, miR-137, miR-34b, and miR-210) and decreased in 1 CpG island (miR-200b) during gastric carcinogenesis[49]. Furthermore, the methylation of those 6 miRNA CpG islands in cells significantly suppressed the expression of the corresponding miRNAs. MiR-137, which acts as a tumor suppressor, was found to be downregulated in GC[50] through methylation of a CpG island in its promotor, and an analysis of clinical samples showed methylation of miR-137 occurred frequently in GC and played a role in gastric carcinogenesis[51]. Methylation-induced miRNA silencing in GC was also observed with miR-335[52], miR-495[53], miR-9[54], miR-10b[55], miR-219-2-3p[56], miR-212[57], miR-941 and miR-1247[58]. Aberrant expression of these miRNAs, and consequent regulation of their corresponding targets, resulted in changes in GC cell growth, invasion and migration[52-56,58]. Furthermore the suppression of miRNA expression was restored after treatment with 5-aza-2'-deoxycytidine, an agent designed to reduce the degree of methylation in GC cells at specific miRNA sites. MiR-129-5p is a multi-drug resistance-related miRNA that becomes down-regulated in the drug-resistant cell line SGC7901/VCR via methylation, as evidenced by a restoration of miR-129-5p levels upon 5-aza-2'-deoxycytidine treatment in these cells[59]. MiR-34c-5p also negatively regulates paclitaxel resistance of GC cells and is down-regulated by a methylation of CpG islands that are near the miR-34 promotor[60]. These experiments show that methylation can regulate the level of miRNA. Conversely, miRNA can regulate DNA methylation by targeting DNA methyltransferases (DNMTs). Previous experiments have shown that miR-148a modulated the expression of DNMT1 and caused the overexpression of miR-148a, and miR-148a reduced the methylation of the RUNX3 promoter, culminating in increased RUNX3 mRNA and protein in GC cells[61].

There are other regulatory elements that can induce aberrant expression of miRNA. For example, TGF-β, a critical cytokine in cancer, can regulate miRNA expression. Specifically, this cytokine can up-regulate miR-155 [62] and miR-181a[63] in hepatocyte cell lines and down-regulate miR-203 through direct binding to the promotor[64]. TGF-β1 treatment has been shown to alter miRNA expression in GC cells, causing the up-regulation of 3 miRNAs and down-regulation of 3 miRNAs[65]. TGF-β1 regulate gene expression in a smad-dependent manner or smad-independent manner. However, the role that TGF-β1 plays in regulating the expression of miRNAs in GC is not often reported and the mechanism still requires elucidation. In addition, certain oncogenes play a critical role in the dysregulation of miRNA in cancer. For example, miR-29b was inhibited by c-myc in non-small cell lung cancer[66] possibly through the regulation of Drosha[67]. P53 has also been reported to modulate the expression of miR-34a[68]; however, this protein has not been found in GC, and the role it plays in miRNA regulation is still uncertain. Hypoxia is another modulator of miRNA expression and functions through HIF-1α. MiR-382 was demonstrated to be induced by HIF-1α in GC cells under a hypoxic stress[69], and this phenomenon was also observed in ovarian carcinoma[70], lung cancer[71] and other cancer cell lines[72-74]. The expression profile of miRNAs also changes in GC when the cells undergo treatment with anti-tumor drugs. Treatment of GC patients with cisplatin and docetaxel significantly increased the expression of members of the miR-29 family, causing an inhibition of GC metastasis[75]. Moreover, some miRNAs that are modulated by anti-tumor drugs, such as miR-508-5p[76], miR-1271[77], miR-503[78] and others, might participate in the development of drug resistance in GC cells[79-82]. MiRNA regulation also occurs at the protein level in GC cell lines. For example GSK3β, a critical protein kinase, suppresses the expression of the miRNA-183-96-182 cluster, resulting in a reduction of miR-96, miR-182 and miR-183 levels in GC cells[83]. Another protein, DDX6, suppresses the expression of the miR-143/145 cluster post-transcriptionally in GC cells[84].

***LncRNAs***

Dysregulation of lncRNAs is involved in tumorigenesis[85], but the underlying mechanisms remain elusive. Here, we describe some the recent published data linked to the mechanisms of dysregulation of lncRNAs in GC.

PVT1 expression is increased in gastric cancer tissues and cells, and the knockdown of PVT1 inhibits GC cell proliferation and lymph node invasion[7,86]. PVT1 shows potential as a novel therapeutic target for patients who would otherwise have a poor prognosis. In addition, HOTAIR was found to be critically involved in the function of GC cells and has an inverse relationship with PCBP-1 in both expression level and function. Accordingly, PCBP1 was confirmed to be an inhibitor of GC pathogenesis. Si-RNA knockdown of HOTAIR in GC cells significantly inhibited cell proliferation, migration and invasion. Additionally, the impact of HOTAIR on apoptosis, cell proliferation and cell cycle regulation were investigated to dissect the carcinogenesis of GC[87,88]. In addition to these findings, HOTAIR is a target of miR-331-3p and miR-124, and therefore, it may act as a competitive endogenous RNA for the targets of those miRNAs[89].

C-Myc induces lncRNA H19 expression, with the expression of lncRNA H19 positively correlating with the c-Myc levels in 80 GC samples[90]. Overexpression of lncRNA H19 directly promotes ISM1 expression and indirectly promotes miR-675 expression in GC. An inverse relationship between the expression of RUNX1 and lncRNA H19/miR-675 in GC tissues and cell lines was also revealed. Overexpression of lncRNA H19 was shown to promote tumorigenic features of GC including proliferation, migration, invasion and metastasis[25,91]. In addition, MALAT1 and MALAT2 were aberrantly highly expressed in gastric cell lines and tissues, and MALAT1 can mediate the over-expression of SF2/ASF in the nucleolus. Therefore, MALAT1 may function as a promoter of GC cell proliferation through the regulation of SF2/ASF[92]. Overexpression of MALAT2 in GC cells increased the migration of GC cells and induced the epithelial–mesenchymal transition (EMT) through a MAP kinase pathway[93].

TUSC7 is a p53-regulated tumor suppressor that acts in part by repressing miR-23b. It has been shown that TUSC7 expression suppressed tumor cell growth *in vitro* and *in vivo*[94]. In addition, the expression of lncRNAs LET, FENDRR, FER1L4 and HMlincRNA717 was markedly down-regulated in tumor tissues compared with adjacent non-tumor tissues. These decreases in specific lncRNA expression were correlated with deeper tumor invasion, lymph node metastasis, distant metastasis, and higher TNM stages[95-98]. However, FENDRR overexpression suppressed invasion and migration by downregulating FN1 and MMP2/MMP9 expression in GC cells[96]. The lncRNA GAS5 was demonstrated to decrease GC cell proliferation partly via regulating E2F1 and P21 expression and to induce apoptosis[99]. Ectopic expression of lncRNA MEG3 was able to inhibit cell proliferation, promote cell apoptosis, and modulate p53 expression in GC cell lines, however its expression level was significantly correlated with TNM stages, depth of invasion, and tumor size[100]. Overexpression of the lncRNA LEIGC was able to suppress tumor growth and cell proliferation and to enhance the sensitivity of GC cells to 5-fluorouracil (5-FU), whereas knockdown of LEIGC had the opposite effect. It was further demonstrated that LEIGC functions by inhibiting the EMT in GC[101].

**FUNCTION AND CLINICAL IMPLICATIONS**

***Survival***

**MiRNAs in cell cycle regulation:** MiRNAs can regulate cell growth by influencing cell cycle-related gene expression. MiR-101 functions as a suppressor in *H. pylori*-infected GC. The ectopic expression of miR-101 results in the downregulation of c-myc, CDK2, CDK4, CDK6, CCND2, CCND3 and CCNE2 and the upregulation of p14, p16, p21 and p27. These changes culminate in the induction of G1-phase cell cycle arrest in GC cells, leading to an inhibition of cell growth and colony formation[102]. MiR-137 suppresses GC cell proliferation both *in vitro* and *in vivo*, through the induction of a G1/S arrest by targeting CDK6[103]. MiR-520d-3p downregulates c-myc and CyclinD1 expression in GC cells and suppresses cell growth by binding to the 3’UTR of EphA2 mRNA[104]. MiR-365 expression is reduced at transcriptional level in GC tissue via AKT signaling in a p53-dependent manner. Overexpression of miR-365 suppresses GC cell proliferation both *in vitro* and *in vivo* through direct binding to the 3’UTR of Cyclin D1 and cdc25A mRNAs[105]. Some miRNA, including miR-300, are involved in regulating cell cycle arrest caused by ionizing radiation such as X-rays, indicating that this miRNA may play a role in regulating the GC cell cycle[106]. The MiR-191/425 cluster was found to be overexpressed in GC tissue. A loss-of-function assay indicated that the cluster has roles in cell cycle regulation, although the mechanism is unknown[107]. MiR-1207-5p and miR-1266 are both reported to reduce the expression of hTERT, resulting in G1/S cell cycle arrest and reduction of GC cell growth both *in vitro* and *in vivo*[108]. MiR-212 inhibited GC cell growth by directly reducing RBP2 expression and upregulating critical cell cycle related proteins such as p21 and p27[109]. MiR-17-5p/20a acted as oncogene in GC cells by directly targeting p21 and TP53INP1, which have negative roles in the cell cycle and promote GC cell growth when inhibited[110]. Some miRNAs, such as miR-101, miR-137, miR-520d-3p and miR-17-5p/20a, directly bind to the 3’UTR of cell cycle related mRNAs and reduce their expression, resulting in progression or arrest of the cell cycle[35,102,103,110]. Other miRNAs, such as miR-300, miR-191/425 cluster, miR-1207-5p, miR-1266 and miR-212[106-109], indirectly modulate cell cycle related protein levels by regulating the expression of upstream target genes, but it is unclear how these miRNA affect the cell cycle. Changing a single factor may cause a series of diversifications of the signaling network in cell cycle activity, and the mechanisms by which this occurs still require further research and exploration.

**Regulation of AKT pathway by miRNAs:** The AKT pathway is dysfunctional and hyperactive in many human cancers, including GC, and plays an important role in cell survival. MiRNAs can regulate cell survival through activation or inactivation of the AKT pathway through their targets in GC. For example, miR-1274a was found to be up-regulated in GC tissue as well as in GC cell lines such as HGC27, MGC803, SGC-7901 and AGS. Interestingly, miR-1274a inhibits FOXO4 protein expression in HGC27 and MGC803 with no effect on mRNA level. A dual-luciferase reporter assay confirmed that FOXO4, which functions as an inhibitor to the PI3K/AKT pathway, was directly modulated by miR-1274a in GC cells. MiR-1274a therefore activates the PI3K/AKT pathway through inhibition of FOXO4 expression in GC cells, resulting in enhanced cell proliferation and migration. GC xenograft mouse models also indicate that miR-1274a overexpression in GC cells can promote tumorigenesis[111]. While miR-542-3p is normally expressed at a low level in GC tissues and cells, overexpression of miR-542-3p can potentially markedly inhibit the activation of the AKT pathway and reduce cell growth by directly binding to the 3’UTR of AEG-1[112]. MiR-137 could inhibit the activation of the AKT pathway through its target gene Cox-2 and suppress GC cell growth both *in vitro* and *in vivo*[50]. MiR-34a[113], miR-338[114,115], miR-21[116], miR-124[117], miR-10b[118] and other miRNAs can also regulate AKT pathway activity through similar gene targeting. Overexpression of miR-126, which normally acts as a suppressor of angiogenesis in GC, also inhibited cell growth by reducing the activation of the AKT pathway[119]. Similarly, hypoxia-induced miR-382 expression reduced the level of PTEN in GC cells causing an inhibition of AKT pathway. *In vivo*, down-regulation of miR-382 caused a reduction of tumor growth and reduced microvessel density[69]. The miR-29 family contains three miRNAs with identical seed sequences: miR-29a, miR-29b, miR-29c. This family was reported to reduce the expression of AKT2, a key member of AKT pathway, by directly targeting its 3’UTR in GC cell lines HGC27 and MGC803. Clinical GC tissue analysis also illustrated that the expression of miR-29 and AKT2 have a negative correlation. Finally, ectopic expression of miR-29 induced a suppression of the AKT pathway in GC cells[120]. In addition to the miR-29 family, let-7b/g also directly binds to the 3’UTR of AKT2 and subsequently results in an inhibition of AKT pathway activity in GC [121].

**MiRNAs in apoptosis:** Inducing or inhibiting cell apoptosis is also an important function of miRNAs in GC cells, making them important regulators of tumor suppressors and oncogenes. Generally, miRNAs that are down-regulated in GC tissues and cells have tumor suppressive functions, and some, including miR-449a[122], miR-133a[123,124], miR-224[125], miR-338[114,115,126], miR-143[127], miR-874[128] and others, are capable of inducing cell apoptosis in GC cells. Overexpression of these miRNAs induces a suppression of cell proliferation in GC cells concurrent with other effects such as cell cycle arrest, and suppression of invasion and metastasis. Tumor suppressive miRNAs have complex functions in GC cells through their known targets or potentially other pathways and may be useful targets for GC therapy. Because miR-449a acts as a tumor suppressor by directly targeting bcl-2, which is known for its anti-apoptotic function, the overexpression of miR-449a in GC cells enhances cell apoptosis and results in G1/G0 arrest[129,130].

MiRNAs can also act as oncogenes to promote tumor growth and are referred to as oncomirs. MiR-183 is an oncomir that is up-regulated in GC tissues, and its increased expression level is associated with high clinical stage cancers, enhanced invasion, and lymph node metastasis. Moreover, overexpression of miR-183 in GC cells reduces the rate of apoptosis by affecting the expression of PDCD4[131]. Other miRNAs, such as miR-645[132], miR-181a[133], miR-942[134], and others, can act as oncomirs by inhibiting cell apoptosis and promoting tumor growth.

NF-κB signaling has been shown to interact with miRNAs in GC cells. IL-1β activates NF-κB in GC cells, and the activated NF-κB directly binds to the promoter of miR-425 to enhance its transcription. Up-regulated miR-425 promotes GC cell proliferation and helps the cells resist apoptosis induced by cisplatin through direct targeting of the PTEN mRNA’s 3’UTR[135]. Alternatively, some miRNAs, such as miR-362, are capable of activating the NF-κB signaling pathway in GC cells[136]. MiR-362 activates the NF-κB signaling pathway by reducing the expression of the tumor suppressor CYLD, which is its direct target in GC cells. Similar to previously mentioned miRNA, the activation of NF-κB through overexpression of miR-362 inhibited the apoptosis induced by cisplatin and promoted GC cell proliferation. MiR-500 also activates NF-κB by suppressing the expression of CYLD, OTUD7B and TAX1BP1, which are all negative regulators of NF-κB signaling. Overexpression of miR-500 leads to activation of NF-κB signaling in GC cells, and promoted resistance to apoptosis, resulting in cell proliferation and high tumorigenicity *in vivo*[137].

**MiRNAs in drug resistance:** Tumor resistance to chemotherapeutic drugs has become increasingly problematic in GC. Recent findings show that miRNAs affect the sensitivity of cancer cells to chemical drugs in GC by regulating the expression of target genes. Using a miRNA expression profiling chip, it was reported that there was a significant dysregulation of miRNAs in the drug resistant sublines SGC-7901/VCR and SGC-7901/ADR compared with the parental SGC-7901 line. Quantitative RT-PCR analysis demonstrated that miR-99b-5p, let-7e-5p, miR-125a-5p, miR-181a-5p and miR-100-5p were significantly down-regulated, and miR-1273g-3p, miR-378a-5p and miR-425-5p were up-regulated in drug resistant sublines[138]. Up-regulated miRNAs in drug resistant sublines prevent cancer cell death induced by chemotherapeutics, while down-regulated miRNAs promote cancer cell death during chemotherapeutic treatment.

MiR-106a was found to be up-regulated in the drug resistant sublines SGC-7901/VCR and SGC-7901/ADR. Overexpression of miR-106a was able to reduce the sensitivity of SGC-7901 to anticancer drugs and inhibit cell apoptosis. Conversely, inhibition of miR-106a in SGC-7901/VCR enhanced the sensitivity of SGC-7901/ VCR to chemotherapeutics and decreased their IC50 dose[81]. MiR-21 was up-regulated in SGC7901/DDP, a cisplatin resistant cell line and may be partially responsible for resistance of GC cells to cisplatin[80]. MiR-19a/b has also been shown to regulate the resistance of GC cells to anticancer drugs and was found to be up-regulated in MDR cell lines. Furthermore, increases in miR-19a/b levels reduces the sensitivity of GC cells to drugs by accelerating ADR efflux[79].

In contrast, MiR-185 was down-regulated in GC tissues. GC cells with significant overexpression of miR-185 were significantly more sensitive to apoptosis induced by low-doses of chemotherapeutic agents compared with their negative controls, a finding which was confirmed in a nude mouse model. Furthermore, reduction of endogenous miR-185 expression in GC cells inhibits cell apoptosis induced by high-dose chemotherapeutic agents[139]. MiR-218 on the other hand, could increase the sensitivity of GC cells to cisplatin and inhibit cell growth[140], and miR-1271 was found to be down-regulated in the cisplatin resistant cell line SGC7901/DDP. Overexpression of miR-1271 enhanced the response of SGC7901/DDP cells to cisplatin[77]. Finally, miR-200c was also reported to regulate drug resistance in GC cells[141].

Accumulating evidence indicates that miRNAs play an important role in the resistance of cancer cells to chemotherapy treatment; however the mechanism by which this occurs remains poorly understood. However, the ability of the previously mentioned miRNAs to directly affect drug resistance in tumor lines reveals novel targets for improving the efficacy of chemotherapy in the future. Therefore, chemotherapy in combination with gene therapy might be a new avenue for cancer treatment going forward.

**LncRNAs in cell survival:** Thousands of lncRNAs were found to be dysregulated in GC tissues compared with adjacent tissues using a microarray analysis, and several lncRNAs from the microarray were confirmed through real-time PCR assays[142,143]. Aberrantly expressed lncRNAs in GC consistently participated in key tumorigenic functions, including growth, drug-resistance, and metastasis, and their presence in the tumor indicated a poor prognosis in GC patients[86,95,144,145]. The expression of several of the dysregulated lncRNAs were correlated with tumor size, TNM stage, histologic grade, differentiation, lymphatic metastasis, invasion and other classifications, including SUMO1P3[146], LINC00152[147], FER1L4[98], HMlincRNA717[97], ABHD11-AS1[148], AC138128.1[149], CCAT1[150], HIF1A-AS2[151] and more. In addition to alterations observed in GC tissue, several lncRNAs were found to have a significantly different expression pattern in serum and gastric juice. For example, CUDR, LSINCT-5 and PTENP1 were down-regulated in the serum of GC patients compared with healthy subjects[152], while AA174084 had a high expression level in gastric juice from GC patients compared with healthy control patients or patients suffering from other non-cancer diseases, such as minimal gastritis, gastric ulcers and atrophic gastritis[153]. In addition, plasma H19 levels were up-regulated in GC patients compared with healthy controls but were down-regulated in postoperative specimens[154]. Together, these features reveal that lncRNAs play significant roles in the survival of cancer cells.

LncRNAs involved in cell proliferation, including HIF1A-AS2[151], MEG3[100], MALAT1[92], CCAT1[155], and LEIGC[101], were identified, however the mechanisms by which these lncRNAs regulate cell growth is still unclear. In addition, PVT1 was up-regulated in GC tissues, and knockdown of PVT1 resulted in a significant inhibition of cell proliferation. Furthermore, PVT1 regulates the cell cycle by binding to EZH2, an important subunit of the PRC2 complex, and inhibits cyclin-dependent protein kinase inhibitors p15/p16[7]. SPRY4-IT1 was also found to be up-regulated in GC tissues and was found to control cell growth, colony formation, cell migration and invasion in GC cells partially through regulating the expression of cyclinD1, MMP2 and MMP9[156]. GAS5 is a lncRNA that is down-regulated in GC tissues, and ectopic expression of GAS5 in GC tumors inhibited cell growth and induced apoptosis both *in vitro* and *in vivo* through regulation of the expression of E2F1 and P21 in GC cells[99]. GHET1 physically binds to insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1), and this process promotes IGF2BP1 binding to c-Myc mRNA, resulting in increased stability of c-Myc mRNA and GC cell growth[157]. HULC, a lncRNA that is up-regulated in GC tissues and cells, is able to reduce cell apoptosis mainly by activating autophagy in the SGC-7901 cell line[158]. In addition to their role in traditional cancer growth, lncRNAs are also heavily involved in the process of drug resistance in GC. The lncRNA PVT1 is not only overexpressed in GC tissues but also in SGC7901 paclitaxel-resistant cells, which indicates that it has a role in the process of GC cell resistance to paclitaxel, which so far is poorly understood[86]. In the multidrug-resistant GC cell sublines SGC7901/ADR and SGC7901/VCR, the level of MRUL was increased significantly. Knockdown of MRUL in these two multidrug-resistant sublines enhanced their sensitivity to chemotherapeutic drugs and led to an increased rate of apoptosis induced by adriamycin or vincristine[159]. AK022798 is another lncRNA involved in the resistance of GC cells to cisplatin. This lncRNA was induced by Notch 1 and overexpressed in cisplatin-resistant GC cell lines. The up-regulated AK022798 enhanced the expression of multidrug resistance- associated protein 1 (MRP1) and P-glycoprotein, thereby resulting in a suppression of apoptosis induced by cisplatin and formation of cisplatin-resistant sublines SGC7901/DDP and BGC823/DDP. This evidence suggests that AK022798 plays a significant role in the development of tumor drug resistance[10].

H19 had been demonstrated to play a critical role in GC function. H19 was found to be overexpressed in GC tissues, and it promotes GC cell proliferation[160]. Further studies suggest that c-Myc enhances the expression of H19 in GC cells, which was supported by a positive correlation between H19 and c-Myc in clinical samples[90]. MiR-675 is expressed concurrently with H19 in GC and is a known product of H19. H19/miR-675 promoted significant GC cell growth directly upon binding to RUNX1[91]. However, another mechanism of H19/miR-675 in promoting carcinogenesis has also been uncovered. Although H19 acts in a similar manner as miR-675, it was found that H19 binds to ISM1 and miR-675 also targets to CALN1 in GC cells, indicating that H19 has other functions besides generating miR-675[25].

In addition to protein interactions, lncRNAs could also be interacting with miRNAs in GC cells. ANRIL is up-regulated in GC tissues and its expression is correlated with TNM stage and tumor size in clinical samples. GC cell proliferation was significantly reduced *in vivo* and *in vitro* by reducing ANRIL expression, and the role of ANRIL in regulating cell growth was shown to be partially through inhibition of miR-99a/miR-449a levels[161]. TUSC7 suppressed the growth of GC cells by reducing miR-23b expression, which is a promoter of cell proliferation[94]. Conversely, lncRNAs can also act as targets of some miRNAs. HOTAIR is a target of miR-331-3p and miR-124 and binds with them directly in GC cells. Furthermore, HOTAIR can regulate the expression of HER2 mRNA when induced by miR-331-3p binding similar to a “sponge”[89]. Often the expression of lncRNAs is regulated by miRNAs, and for example, AC130710 is a target of miR-129-5p and is down-regulated via ectopic expression of miR-129-5p in GC cells[162].

***Metastasis***

**MiRNAs as oncogenes:** miR-27 promotes GC cell metastasis by inducing EMT[163]. Moreover, single nucleotide polymorphisms (SNP) of miRNA genes lead to functional losses or disorders of the miRNA that are generally associated with SNPs. The G/A polymorphism in the miR-27a gene (rs11671784) directly decreases miR-27a expression. MiR-27 is responsible for directly blocking the expression of the tumor suppressor gene APC, and thus, the loss of its function contributes to EMT[164]. MiR-21 is an important oncogene that is ivolved in many tumorigenic factors, including metastasis and invasion, cell cycle, tumor size, and growth[165,166]. MiRNA-21 promotes tumor invasion in GC by targeting PTEN[167]. Furthermore, high levels of miRNA-21 expression is positively correlated with lymph node metastasis in GC[168]. MiRNA-21 is highly expressed in GC and is negatively correlated with PDCD4 expression, suggesting that PDCD4 is a direct target gene of miRNA-21 that inhibits cell invasion through targeted inhibition. PTEN is a well-known tumor suppressor gene that is also shown to be a direct target of miRNA-21[169]. Upregulation of the members of miR-106b family (miR-106b, miR-93, and miR-25) in CD44(+) GC cells reduces the expression of smad7, an inhibitor of the TGF-β/Smad signaling pathway. Overexpression of miR-106b family miRNAs in CD44(+) GC cells promotes cancer stem cell-like properties and particularly EMT characteristics by activating the TGF-β/Smad signaling pathway[170]. MiR-210 is often highly overexpressed in GC and is regulated by HIF-1α. Due to this regulation, miRNA-210 expression is significantly increased in hypoxic environments where EMT develops. Unlike previously mentioned miRNAs, MiR210 has been associated with *H. pylori* infection[171]. MiRNA-210 up regulation induces significant migration and invasion of GC cells. Aside from the above-mentioned miRNAs, highly homologous miRNAs play a role in GC cell biology. For example, overexpression of miR-196a/-196b enhances GC cell migration and invasion through inhibitory oligonucleotides or direct targeting of radixin promoters in GC cells[172]. MiR-19a/b is overexpressed in GC tissues and significantly associates with the onset of metastasis. Although MXD1 is a direct target of miR-19a/b, its overexpression reduces both miR-19a/b and c-myc levels[173]. Moreover, some miRNAs directly target genes to regulate metastasis and invasion in GC cells. MiR-214 and miR-21 regulate GC cell migration and invasion by targeting PTEN[79]. In addition, miR-199a-5p acts as an oncogene in GC and functions by targeting klotho[174]. However, these are far from the only miRNA controllers that are involved in metastasis and tumor invasion through the regulation of protein signaling networks in GC cells.

**MiRNAs are capable of acting as tumor suppressor genes:**The miRNA-200 family suppresses GC cell metastasis by reducing the expression of the transcription factor Zeb, and thereby decreasing E-cadherin expression and reducing the occurrence of EMT[175,176]. E-cadherin is a direct target of miRNA-9, and in addition, there are many miRNAs that function by targeting the EMT transcription factors Snail, Snail2, Zeb1 and Zeb2, which regulate signaling pathways controlling tumor metastasis. The tumor suppressor gene p53 can induce the expression of miR-34a and miR-192, which inhibits the expression of Snail-1 and Zeb-2, thus preventing the EMT process[177]. MiRNA-1182 targets the open reading frame of hTERT and serves to lower hTERT expression, inhibiting cell migration in GC[178]. MiRNA-146a inhibits migration and invasion in GC cells by downregulating EGFR and IRAK gene expression[179]. In addition to these functions, miRNA-146a/b downregulates UHRF1 by directly targeting its 3’UTR, and this effect in turn reactivates the slit homologue3, cadherin4, and RUNX3 genes via promoter demethylation. MiRNA-146a/b plays a key role in regulating the metastatic process in GC cells[180]. MiRNA-328-induced downregulation of CD44v9 expression occurs in *H. pylori*-infected gastric mucosa adjacent to GC tumors, which decreases the rate at which stem cells transform into GC cells[181]. In summary, abnormal expression of miRNA has been consistently observed in GC tissues. The proteins shown to be dysregulated in GC are actually being driven by a massive miRNA expression imbalance, leading to metastasis and invasion in these tumors.

**Dysregulated lncRNA expression:** LncRNA HOTAIR plays a role in metastasis in GC cells. LncRNA PCBP-1 and HOTAIR have an inverse relationship in both expression level and function. PCBP1 has been confirmed to inhibit GC pathogenesis, and overexpression of HOTAIR downregulates PCBP1 protein levels. HOTAIR expressed in xenograft GC tumors *in vivo* increases metastasis[89,182]. In addition, HOTAIR is a known target of miR-331-3p and miR-124 and may act as a competitive inhibitor to endogenous RNAs[89]. The lncRNA H19 actively binds to ISM1, but its expression is positively correlated with that of H19, leading to miR-675 targeting of CALN1. While overexpression of H19 directly promotes ISM1 expression and indirectly promotes miR-675 expression in GC, CALN1 is a target of miR-675. H19 mediates this process to promote GC cell metastasis[25]. In addition, lncRNAs are capable of mediating gene expression. For example, SNCG upregulation by lncRNA AK058003 mediates hypoxia-induced GC cell metastasis. SNCG and AK058003 expression has been shown to be increased by hypoxia[183]. LncRNA HULC positively regulates GC cell migration and invasion, and the deletion of HULC reverses EMT, indicating that HULC plays a role in EMT regulation[158]. FENDRR overexpression suppresses the invasion and metastasis of GC cells by downregulating FN1 and MMP2/MMP9 expression[96]. High linc-UBC1 expression is correlated with lymph-node metastasis, and inhibition of linc-UBC1 suppresses the invasion of GC cells[184]. Silencing of SDMGC or TRIM16 decreases cell invasion and migration rates, while up-regulation of SDMGC or TRIM16 is able to promote invasion and migration[185]. Compared with the comprehensive catalogue of miRNAs uncovered, the majority of lncRNA functions are unknown and those shown to be functional have unclear mechanisms. It is understood that a few lncRNAs can mediate the expression of oncogenes or tumor suppressor genes, and dysfunction of these lncRNAs can result in GC cell metastasis and invasion. Similar to miRNAs, not only can lncRNAs only take part in post-transcriptional regulatory activities by binding to the mRNA, but they can also regulate mRNA indirectly by competitively binding with miRNA. Currently, lncRNA research remains a small part of the overall GC field, however we think lncRNAs represent very important targets for clinical applications in the treatment of this disorder.

**Angiogenesis**

Angiogenesis is an important step during the development of cancer[186]. MiRNAs, acting as post-transcriptional regulators, are also involved in regulating angiogenesis. MiR-874, which is down-regulated in human GC, could potentially repress the expression of STAT3 by directly targeting the 3’UTR of its mRNA, resulting in a repression to the STAT3/VEGF-A pathway and significantly inhibiting tumor angiogenesis of GC cells[187]. Overexpression of miR-18a inactivated the mTOR pathway and downregulated HIF1α and VEGF expression in SGC-7901 cells in addition to causing a substantial reduction in the number of microvessels in a SGC-7901 xenograft model[188]. MiRNA-145 also acts as an inhibitor of angiogenesis in GC cells, primarily by directly binding to 3’UTR of the Ets1 mRNA[189]. Hypoxia can induce expression of miRNAs, which may play a role in promoting angiogenesis. MiR-382, which is up-regulated by hypoxia, activates the AKT/mTOR signaling pathway by directly suppressing PTEN and therefore induces angiogenesis via VEGF. This evidence indicates that miR-382 is an angiogenic oncogene in GC cells under hypoxic conditions[69]. VEGF-A is a critical factor in the regulation of angiogenesis, so miRNAs that can impact VEGF-A expression should have a function in angiogenesis. For example: miR-126 was found to directly bind to the 3’UTR of VEGF-A in GC cells and therefore could inhibit angiogenesis both *in vitro* and *in vivo*[119]. In addition, lncRNAs also participate in the regulation of tumor angiogenesis. For example, MALAT1 regulates vascular growth in human endothelial cells[190], and hepatocellular carcinoma-related MVIH can activate angiogenesis *in vivo*[191]. However, thus far no lncRNAs that have been shown to impact angiogenic regulation are reported in GC cells or tissues.

**Clinical implications**

***MiRNAs as biomarkers***

MiRNAs have the potential to be biomarkers for swift gastric cancer identification in the clinic. MiRNAs have several large advantages as biomarkers: they are highly specific, with each tissue, including tumor tissue, having its own characteristic miRNA expression profiling; miRNAs are very stable and are resistant to RNAse enzymes and changes in their physical state (*i.e.*, temperature, pH and other environmental conditions); miRNAs are easy to detect, with conventional methods such as RT-PCR, and gene chip analysis. However, miRNAs still have several major issues that must be addressed before they can be incorporated as cancer biomarkers: miRNA analysis cannot function on a small sample size, and require a large-scale standardized survey; a reference range detailing the possible miRNAs active in tumors must be created; when looking for cancer metastasis, recurrence and prognosis biomarkers, it is necessary to continue to follow up with more large scale patient data to further define the cancer progression; to be used as biomarkers, detection of peripheral blood miRNA requires the establishment of a standardized system that includes sample collection, preservation and testing to ensure the accuracy and repeatability of miRNA detection.

At present, because of the high rate of clinical GC, many researchers have opted to select patients with GC to compare their tumor tissues to their own normal tissue samples using microarray analysis. These experiments show significant miRNA increases or decreases in patients with GC. These experiments can then be used to identify key differences between cancer and normal tissue biopsy expression, and real-time PCR validation can be used to determine the accuracy, specificity and sensitivity of those markers.

*MiRNA: potential biomarkers for gastric cancer diagnosis:* To detect differential expression in the miRNA of GC tissues, researchers usually identify patients with GC tissues and adjacent non-transformed tissues. In addition, some researchers utilize GC tissues and compare those samples to normal tissues of other independent patients. Researchers have found that some patients’ non transformed tissue samples show increased expression of miRNAs such as miR-17, miR-106a, and miR-20a, and others show decreased expression of other miRNAs such as miR-23a, miR-150, and miR-130a[192], indicating a significant difference in miRNA profiles between non-transformed tissue samples. It is found that miR-30b[193], miR-148a[194], miR-143 and miR-195[195] are down-regulated in GC tissues compared with their matched adjacent non-tumor gastric tissues, and tend to be down-regulated in many GC cell lines. MiR-30b has the potential to be a novel tumor suppressor gene, promoting apoptosis and suppressing tumor growth by targeting plasminogen activator inhibitor-1. MiR-148a has an unknown mechanism, but could regulate several different target genes and signaling pathways involved in tumor proliferation, invasion and metastasis. MiR-375 is significantly downregulated in distal gastric adenocarcinoma tissues and the circulating serum. In addition, this miRNA has been linked to *H. pylori* infections[196,197]. Studies have found that the levels of miR-106a and miR-21 are significantly higher in GC tissues[195,198] and are found at low levels in gastric juice[199]. Accordingly, miR-21 is likely a risk factor that could be useful for prognosis, particularly as it is also found to be similarly increased in plasma[200]. Studies have also found that many other miRNAs are differentially expressed in GC. For example, miR-31 expression is reduced, and miR-421 is over expressed, among others. These samples have been collected from different races and regions, however the data require more samples and appropriate statistical treatment to verify the presence of biomarkers. In addition, upregulation of miR-21 and downregulation of miR-133b are detectable in both gastric and esophageal cancers[201]. However, because the detection of differential expression in GC tissues is a significantly invasive procedure for patients, these markers are not suitable for initial clinical diagnosis.

Clinically, detecting differences in the serum or plasma of patients is more useful than tissue sample analysis because blood work is relatively non- invasive and easy to obtain. With more insight into blood miRNA expression during GC, it is possible to identify markers that are not only suitable for diagnosis but also can guide treatment and prognosis. In serum samples, miR-233, miR-16, and miR-100 have increased expression in patients with GC. These markers correlated significantly with clinical characteristics of GC patients, such as their TNM stages[202]. In addition, plasma miR-222 was significantly upregulated in GC patients compared with chronic atrophic gastritis and healthy controls and also correlated with patients’ clinical stages and lymph node metastasis status[203]. Some micro-RNAs that are abnormally expressed in other tumor, have a similar expression pattern in GC. Circulating miR-18a is one such miRNA, which shows altered expression in both GC and bladder cancer[204]. MiR-let-7 regulation is sabotaged in GC, [breast cancer](http://www.ncbi.nlm.nih.gov/pubmed/25277099)[205], [oropharyngeal cancer](http://www.ncbi.nlm.nih.gov/pubmed/25127693)[206], and [lung cancer](http://www.ncbi.nlm.nih.gov/pubmed/23981581)[207]. These markers represent the potential for an extensive screening test that may be able to identify a variety of nascent cancers in patients. In plasma samples, miR-16-5p and miR-19b-3p are down regulated, and can be used to distinguish healthy patients from GC patients with a variety of different TNM stages and differentiation grades, including the early stages of the cancer[208]. Several miRNAs found in serum samples are predictively consistent with GC standards in the industry, including mic-RNA-421, which has been shown to have a higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in GCs[209,210]. In addition to these markers, certain mic-RNAs in the blood showed altered levels unrelated to the presence of cancer, most likely due to the occurrence of hemolysis in the patient samples.

In addition to the patient's blood and stomach tissue, their gastric juice can also be used to detect increased risk of GC. Samples of gastric juice are usually collected from normal gastric mucosa, gastritis, and GC, therefore a wealth of potential biomarkers await investigation. For example, investigators found that miR-129-1-3p and miR-129-2-3p are decreased in GC[211]. In addition, miR-21 and miR-106a are decreased in GC, which also correlates with patients’ TNM stage. High expression of miR-21 and miR-106a occurs in intestinal GC types compared with diffuse GC types[199]. Furthermore, miR-21 and miR-106a are also upregulated in gastric carcinoma tissue.

***MiRNA***

**Evaluation of potential biomarkers of** **prognosis:**In addition to their potential as diagnostic markers, the expression levels of specific micro-RNAs can also be used as prognostic markers, as several micro-RNA expression changes that appear to suggest poor prognosis. These include the down-regulation of miR-451, which is associated with poor prognosis. Furthermore, the overexpression of miR-451 increased tumor sensitivity to radiotherapy[212]. MiRNA can be combined with other proteins as part of a comprehensive combination marker. An example of this is miR-200c, which forms a complex with GDF15 and is indicative of poor outcomes in GC patients[213]. Many diagnostic markers may also have prognostic value; however, significant work will need to be conducted to confirm their role in prognosis.

Certain miRNAs act as key regulatory hubs, controlling a significant portion of the cancer cell’s signaling network, and the reregulation of any one of them may be a marker for growth and metastasis. MiR-214 is one example of these key miRNAs[214]. Some miRNAs, such as miR-133a[123] and miR-29c[215], are known to function as tumor suppressors. The expression of these miRNAs was significantly decreased in GC, and their deregulation was associated with lymph node metastases in GC patients. MiR-133a suppresses TAGLN2 at the transcriptional and translational levels, while MiR-29c directly targets ITGB1. Overexpression of miR-133a inhibits cell growth and invasion and induces cell apoptosis and cycle arrest through the repression of the TAGLN2 gene, which makes it a candidate as a biomarker or a therapeutic target. Loss of miR-29c expression is an early event in the initiation of gastric carcinogenesis, which makes it attractive as a diagnostic and therapeutic biomarker for patients with GC. MiR-29c also plays a role in the efficacy of chemotherapy, and suppresses metastasis in GC[75].

Cancer stem cells are characterized by their strong tumorigenicity. In GC stem cells that express CD44, miR-106b expression is increased, activating TGF-β/Smad signaling in GC cells. This phenomenon leads to a strong invasion and migration impetus for the stem cell population.In a miRNA microarray, the miR-106b family composed of miR-106b, miR-93, and miR-25 is significantly upregulated in CD44(+) cells compared to CD44(-) cells[170], which also significantly correlates with tumor size, borrmann type and TNM stage (*P* < 0.05) in GC patients[216].

**Lnc-RNA and prognosis**

In addition to miRNA, lnc-RNAs can promote tumor cell expression of CD44, causing those tumor cells to exhibit stem cell properties. One example is the lncRNA GAPLINC (gastric adenocarcinoma predictive long intergenic noncoding RNA)[217]. Typically, these non-coding RNAs have prompted high tumor aggressiveness, and lead to a poor prognosis. GAPLINC overexpression currently defines a subgroup of patients with GC with very poor survival outcomes.Mechanistic investigations show that GAPLINC regulates CD44 as a molecular decoy for miR211-3p, a miRNA that targets both molecules. Another lncRNA, ANRIL recruits and binds to PRC2，and is up-regulated in GC tissues. Knocking down ANRIL can repress the proliferation of GC cells both *in vitro* and *in vivo*. E2F1 induces ANRIL and ANRIL-mediated growth promotion [by epigenetically silencing miR-99a/miR-449a.](http://www.ncbi.nlm.nih.gov/pubmed/24810364) Like GAPLINC, the presence of ANRIL indicates a poor prognosis for patients[161]. Overexpression of the lncRNA HOTAIR is characteristic of poor prognosis in GC, and may confer an as of yet unknown malignant phenotype to tumor cells. It functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in GC[89]. HER (human epidermal growth factor receptor) based cancers, such as HER2-positive breast cancer and GC, often show MiR-337 and miR-302f overexpression, and MiR-139 and miR-129 underexpression[218].

In tumor cells, the regulatory interactions between lncRNAs, miRNAs and proteins are complicated and unknown. It is important not just to look at statistical markers but also to attempt to identify the mechanisms by which these molecules interact with each other to understand the full scope of the regulatory network altered by tumorigenic mutations. For now, technology is limited, but it is also important to obtain more samples for comprehensive studies.

**CONCLUSION**

Recently, accumulating evidence is revealing that non-coding RNA plays a more critical role in cancer than has been thought for decades. As we have summarized and discussed in this review, Non-coding RNA (ncRNAs) participate in every stage of cancer, including tumorigenesis, growth, apoptosis, cell cycle regulation, metastasis, angiogenesis, and drug resistance. Hundreds of ncRNAs have been shown to be dysregulated in tissues and cell lines, often with each sequence functioning as a tumor promoter or inhibitor. However, the mechanism driving aberrant expression has been unclear until now. We described factors that can regulate miRNA expression in GC, such as *H. pylori* infection, DNA methylation, cytokine exposure, and hypoxia. NcRNAs act as key regulators in cell processes, and their levels vary to regulate the expression levels of their targets, leading to a normal growth and differentiation. Once cells suffer from carcinogenic alterations, the regulation of ncRNA levels become dysregulated, leading to cell survival in cancer lines. If the process of the cells’ tumorigenesis cannot be stopped, the gene expression of these malignant cells will fundamentally change and a new ncRNA profile will emerge. This new profile often involves the down regulation of anti-tumor ncRNAs and upregulation of ncRNAs that promote the survival of malignant cells and the initial formation of the tumor. However, some miRNAs that are up-regulated in GC tissues and cells also act as tumor suppressors. This may be explained by the presence of a negative feedback loop effect, such as the case with miR-146a. It is difficult to explain the mechanism of ncRNAs in the process of malignant transformation because it is unclear whether ncRNAs are a driving force behind the transformation or a result of it. Regardless, the abnormal expression of ncRNAs indicates a novel method to diagnose cancer, especially in its early stages. Some ncRNAs are secreted into blood, gastric juice, or urine and this facilitates the acquisition of samples for biomarker analysis with little discomfort to the patient. Some ncRNAs can also indicate a different prognosis for patients based on their presence or their expression level in clinical testing. In addition to use as biomarkers, abnormally expressed ncRNAs may be potential candidates for cancer therapy.

Moreover, some miRNAs directly target genes to regulate metastasis and invasion in GC cells. MiR-214 and miR-21 regulate GC cell migration and invasion by targeting PTEN. MiR-199a-5p acts as an oncogene in GC and functions by targeting klotho. Some miRNAs control metastasis and invasion through the regulation of signaling networks in GC cells. MiRNAs regulate gene expression through post-transcriptional repression and can act to control multiple cellular pathways. Based on the literature, abnormal expression of miRNA has been observed in GC tissues. The proteins that are dysregulated due to aberrant miRNA expression in GC often drive metastasis and invasion in tumor cells. The ideal time for a tumor to invade and metastasize is when the original cancer cells transform into malignancies, as that generally leads to local invasion and distant metastasis. During this process, cancer cells often undergo morphological changes and reduce their contacts to the extracellular matrix. The process by which the cancer cell undergoes metastasis and invasion is very complex. Between continuous signaling, expression of transcription factors, the reduction of cell-cell adhesion proteins, such as cadherin, tumor growth, the changing tumor microenvironment, the tumor stem cells as well as indirect stimulation, it can often result in multiple mutant tumor cell genomes that compete and can accelerate metastasis and invasion of cancer cells. Of course, cancer cells grown in continuous culture do not model natural tumors without exposure to the blood vessels. These vessels function to supply oxygen to tumor cells that have limited nutritional capability, leaving hypoxic conditions within the tumor core and thus promoting tumor cell migration to the blood vessels and lymphatic areas. During metastasis and invasion, cells will detect a more suitable location to grow, although, new colonies will often form at the first viable point rather than at optimal points.

Cisplatin resistance is the most common cause of treatment failure in GC patients. Many cancer chemotherapy treatments fail because of drug resistance, and miRNAs serve as modulators that can adjust the sensitivity of cells to drugs. For example, the miR-223/FBXW7 signaling pathway contributes significantly to DDP resistance of GC cells[82].

From a novel methodology in which the system is capable of identifying more screening markers and more reliable markers[219], fourteen total biomarkers have been found to be associated with GC. Additionally, three miRNAs (miR-211, let-7b, and miR-708) were reported for the first time to differentiate patients with GC and represent possible diagnostic biomarkers for GC.

Polymorphisms of miRNAs primarily occur via a change in their precursor molecule. Mutations of some sites can interfere the expression of mature miRNAs, which in turn impacts their function and can macroscopically affect tumor malignancy. Specific miRNA polymorphism sites can be used as tumor markers for prognosis. For example, the pri-let-7a-2 rs629367 CC genotype, which may increase the risks of GC, possibly affects mature let-7a expression and could therefore serve as a predictive biomarker for high-risk and poor prognosis incidences of GC[220]. LncRNAs are also known for their potential polymorphisms, though specific lncRNA polymorphisms are rarely studied[221]. However, research of this type is gaining more attention[222]. These biomarkers are diverse and complex and could provide the basis for future individualized treatment of GC.

**REFERENCES**

1 **Ferro A**, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. *Eur J Cancer* 2014; **50**: 1330-1344 [PMID: 24650579 DOI: 10.1016/j.ejca.2014.01.029]

2 **Uedo N**, Takeuchi Y, Ishihara R. Endoscopic management of early gastric cancer: endoscopic mucosal resection or endoscopic submucosal dissection: data from a Japanese high-volume center and literature review. *Ann Gastroenterol* 2012; **25**: 281-290 [PMID: 24714247]

3 **Plummer M**, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. *Int J Cancer* 2015; **136**: 487-490 [PMID: 24889903 DOI: 10.1002/ijc.28999]

4 **Wang X**, Li Y, Xu G, Liu M, Xue L, Liu L, Hu S, Zhang Y, Nie Y, Liang S, Wang B, Ding J. Mechanism study of peptide GMBP1 and its receptor GRP78 in modulating gastric cancer MDR by iTRAQ-based proteomic analysis. *BMC Cancer* 2015; **15**: 358 [PMID: 25943993 DOI: 10.1186/s12885-015-1361-3]

5 **Li C**, Liu DR, Li GG, Wang HH, Li XW, Zhang W, Wu YL, Chen L. CD97 promotes gastric cancer cell proliferation and invasion through exosome-mediated MAPK signaling pathway. *World J Gastroenterol* 2015; **21**: 6215-6228 [PMID: 26034356 DOI: 10.3748/wjg.v21.i20.6215]

6 **Li Q**, Gao Y, Xu ZG, Jiang H, Yu YY, Zhu ZG. Effect of antisense oligodeoxynucleotide targeted against NF-κB/P65 on cell proliferation and tumorigenesis of gastric cancer. *Clin Exp Med* 2013; **13**: 11-19 [PMID: 22234797 DOI: 10.1007/s10238-011-0174-1]

7 **Kong R**, Zhang EB, Yin DD, You LH, Xu TP, Chen WM, Xia R, Wan L, Sun M, Wang ZX, De W, Zhang ZH. Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. *Mol Cancer* 2015; **14**: 82 [PMID: 25890171 DOI: 10.1186/s12943-015-0355-8]

8 **Huang TT**, Ping YH, Wang AM, Ke CC, Fang WL, Huang KH, Lee HC, Chi CW, Yeh TS. The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis. *Oncotarget* 2015; **6**: 18012-18026 [PMID: 26041881]

9 **Ma F**, Song H, Guo B, Zhang Y, Zheng Y, Lin C, Wu Y, Guan G, Sha R, Zhou Q, Wang D, Zhou X, Li J, Qiu X. MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1. *Oncotarget* 2015; **6**: 17404-17416 [PMID: 25965817]

10 **Hang Q**, Sun R, Jiang C, Li Y. Notch 1 promotes cisplatin-resistant gastric cancer formation by upregulating lncRNA AK022798 expression. *Anticancer Drugs* 2015; **26**: 632-640 [PMID: 25763542 DOI: 10.1097/CAD.0000000000000227]

11 **Xu TP**, Liu XX, Xia R, Yin L, Kong R, Chen WM, Huang MD, Shu YQ. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. *Oncogene* 2015; Epub ahead of print [PMID: 25728677 DOI: 10.1038/onc.2015.18]

12 **Yu X**, Zhang L, Wen G, Zhao H, Luong LA, Chen Q, Huang Y, Zhu J, Ye S, Xu Q, Wang W, Xiao Q. Upregulated sirtuin 1 by miRNA-34a is required for smooth muscle cell differentiation from pluripotent stem cells. *Cell Death Differ* 2015; **22**: 1170-1180 [PMID: 25526086 DOI: 10.1038/cdd.2014.206]

13 **Hauser B**, Zhao Y, Pang X, Ling Z, Myers E, Wang P, Califano J, Gu X. Functions of MiRNA-128 on the regulation of head and neck squamous cell carcinoma growth and apoptosis. *PLoS One* 2015; **10**: e0116321 [PMID: 25764126 DOI: 10.1371/journal.pone.0116321]

14 **Kong W**, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. *Oncogene* 2014; **33**: 679-689 [PMID: 23353819 DOI: 10.1038/onc.2012.636]

15 **Paschon V**, Takada SH, Ikebara JM, Sousa E, Raeisossadati R, Ulrich H, Kihara AH. Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders. *Mol Neurobiol* 2015; Epub ahead of print [PMID: 25862375]

16 **McDaniel K**, Herrera L, Zhou T, Francis H, Han Y, Levine P, Lin E, Glaser S, Alpini G, Meng F. The functional role of microRNAs in alcoholic liver injury. *J Cell Mol Med* 2014; **18**: 197-207 [PMID: 24400890 DOI: 10.1111/jcmm.12223]

17 **Qu H**, Zheng L, Pu J, Mei H, Xiang X, Zhao X, Li D, Li S, Mao L, Huang K, Tong Q. miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. *Hum Mol Genet* 2015; **24**: 2539-2551 [PMID: 25616966 DOI: 10.1093/hmg/ddv018]

18 **Dai X**, Chen X, Chen Q, Shi L, Liang H, Zhou Z, Liu Q, Pang W, Hou D, Wang C, Zen K, Yuan Y, Zhang CY, Xia L. MicroRNA-193a-3p Reduces Intestinal Inflammation in Response to Microbiota via Down-regulation of Colonic PepT1. *J Biol Chem* 2015; **290**: 16099-16115 [PMID: 25931122 DOI: 10.1074/jbc.M115.659318]

19 **Chen W**, Qin C. General hallmarks of microRNAs in brain evolution and development. *RNA Biol* 2015; **12**: 701-708 [PMID: 26000728 DOI: 10.1080/15476286.2015.1048954]

20 **Aaldering LJ**, Tayeb H, Krishnan S, Fletcher S, Wilton SD, Veedu RN. Smart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapy. *RNA Biol* 2015; **12**: 412-425 [PMID: 25849197 DOI: 10.1080/15476286.2015.1017234]

21 **Merhautova J**, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, Vyzula R, Demlova R, Slaby O. miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. *Biomed Res Int* 2015; **2015**: 941980 [PMID: 26064968 DOI: 10.1155/2015/941980]

22 **Jiang C**, Chen X, Alattar M, Wei J, Liu H. MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. *Cancer Gene Ther* 2015; **22**: 291-301 [PMID: 25998522 DOI: 10.1038/cgt.2015.19]

23 **Powrózek T**, Krawczyk P, Kowalski DM, Winiarczyk K, Olszyna-Serementa M, Milanowski J. Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers. *Transl Res* 2015; Epub ahead of print [PMID: 26079400 DOI: 10.1016/j.trsl.2015.05.009]

24 **Tsujiura M**, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E. Liquid biopsy of gastric cancer patients: circulating tumor cells and cell-free nucleic acids. *World J Gastroenterol* 2014; **20**: 3265-3286 [PMID: 24696609 DOI: 10.3748/wjg.v20.i12.3265]

25 **Li H**, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. *Oncotarget* 2014; **5**: 2318-2329 [PMID: 24810858]

26 **Cao C**, Sun J, Zhang D, Guo X, Xie L, Li X, Wu D, Liu L. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells. *Gastroenterology* 2015; **148**: 415-26.e18 [PMID: 25449213 DOI: 10.1053/j.gastro.2014.10.012]

27 **Gibb EA**, Warren RL, Wilson GW, Brown SD, Robertson GA, Morin GB, Holt RA. Activation of an endogenous retrovirus-associated long non-coding RNA in human adenocarcinoma. *Genome Med* 2015; **7**: 22 [PMID: 25821520 DOI: 10.1186/s13073-015-0142-6]

28 **Yarmishyn AA**, Kurochkin IV. Long noncoding RNAs: a potential novel class of cancer biomarkers. *Front Genet* 2015; **6**: 145 [PMID: 25954300 DOI: 10.3389/fgene.2015.00145]

29 **Necsulea A**, Soumillon M, Warnefors M, Liechti A, Daish T, Zeller U, Baker JC, Grützner F, Kaessmann H. The evolution of lncRNA repertoires and expression patterns in tetrapods. *Nature* 2014; **505**: 635-640 [PMID: 24463510 DOI: 10.1038/nature12943]

30 **Wang Y**, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. *Dev Cell* 2013; **25**: 69-80 [PMID: 23541921 DOI: 10.1016/j.devcel.2013.03.002]

31 **Wang Y**, Huang C, Chintagari NR, Xi D, Weng T, Liu L. miR-124 regulates fetal pulmonary epithelial cell maturation. *Am J Physiol Lung Cell Mol Physiol* 2015; **309**: L400-L413 [PMID: 26071557 DOI: 10.1152/ajplung.00356.2014]

32 **Cohen ML**, Kim S, Morita K, Kim SH, Han M. The GATA factor elt-1 regulates C. elegans developmental timing by promoting expression of the let-7 family microRNAs. *PLoS Genet* 2015; **11**: e1005099 [PMID: 25816370 DOI: 10.1371/journal.pgen.1005099]

33 **Simpson LJ**, Ansel KM. MicroRNA regulation of lymphocyte tolerance and autoimmunity. *J Clin Invest* 2015; **125**: 2242-2249 [PMID: 26030228 DOI: 10.1172/JCI78090]

34 **Chang H**, Kim N, Park JH, Nam RH, Choi YJ, Lee HS, Yoon H, Shin CM, Park YS, Kim JM, Lee DH. Different microRNA expression levels in gastric cancer depending on Helicobacter pylori infection. *Gut Liver* 2015; **9**: 188-196 [PMID: 25167801 DOI: 10.5009/gnl13371]

35 **Ma L**, Chen Y, Zhang B, Liu G. Increased microRNA-223 in Helicobacter pylori-associated gastric cancer contributed to cancer cell proliferation and migration. *Biosci Biotechnol Biochem* 2014; **78**: 602-608 [PMID: 25036956 DOI: 10.1080/09168451.2014.895661]

36 **Li N**, Tang B, Zhu ED, Li BS, Zhuang Y, Yu S, Lu DS, Zou QM, Xiao B, Mao XH. Increased miR-222 in *H. pylori*-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. *FEBS Lett* 2012; **586**: 722-728 [PMID: 22321642 DOI: 10.1016/j.febslet.2012.01.025]

37 **Miao L**, Liu K, Xie M, Xing Y, Xi T. miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling. *Cancer Immunol Immunother* 2014; **63**: 699-711 [PMID: 24718681 DOI: 10.1007/s00262-014-1550-y]

38 **Noto JM**, Piazuelo MB, Chaturvedi R, Bartel CA, Thatcher EJ, Delgado A, Romero-Gallo J, Wilson KT, Correa P, Patton JG, Peek RM. Strain-specific suppression of microRNA-320 by carcinogenic Helicobacter pylori promotes expression of the antiapoptotic protein Mcl-1. *Am J Physiol Gastrointest Liver Physiol* 2013; **305**: G786-G796 [PMID: 24136787 DOI: 10.1152/ajpgi.00279.2013]

39 **Liu Z**, Wang D, Hu Y, Zhou G, Zhu C, Yu Q, Chi Y, Cao Y, Jia C, Zou Q. MicroRNA-146a negatively regulates PTGS2 expression induced by Helicobacter pylori in human gastric epithelial cells. *J Gastroenterol* 2013; **48**: 86-92 [PMID: 22699322 DOI: 10.1007/s00535-012-0609-9]

40 **Baud J**, Varon C, Chabas S, Chambonnier L, Darfeuille F, Staedel C. Helicobacter pylori initiates a mesenchymal transition through ZEB1 in gastric epithelial cells. *PLoS One* 2013; **8**: e60315 [PMID: 23565224 DOI: 10.1371/journal.pone.0060315]

41 **Xiao B**, Liu Z, Li BS, Tang B, Li W, Guo G, Shi Y, Wang F, Wu Y, Tong WD, Guo H, Mao XH, Zou QM. Induction of microRNA-155 during Helicobacter pylori infection and its negative regulatory role in the inflammatory response. *J Infect Dis* 2009; **200**: 916-925 [PMID: 19650740 DOI: 10.1086/605443]

42 **Fassi Fehri L**, Koch M, Belogolova E, Khalil H, Bolz C, Kalali B, Mollenkopf HJ, Beigier-Bompadre M, Karlas A, Schneider T, Churin Y, Gerhard M, Meyer TF. Helicobacter pylori induces miR-155 in T cells in a cAMP-Foxp3-dependent manner. *PLoS One* 2010; **5**: e9500 [PMID: 20209161 DOI: 10.1371/journal.pone.0009500]

43 **Koch M**, Mollenkopf HJ, Klemm U, Meyer TF. Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-damage induced apoptosis. *Proc Natl Acad Sci USA* 2012; **109**: E1153-E1162 [PMID: 22509021 DOI: 10.1073/pnas.1116125109]

44 **Oertli M**, Engler DB, Kohler E, Koch M, Meyer TF, Müller A. MicroRNA-155 is essential for the T cell-mediated control of Helicobacter pylori infection and for the induction of chronic Gastritis and Colitis. *J Immunol* 2011; **187**: 3578-3586 [PMID: 21880981 DOI: 10.4049/jimmunol.1101772]

45 **Tang B**, Xiao B, Liu Z, Li N, Zhu ED, Li BS, Xie QH, Zhuang Y, Zou QM, Mao XH. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. *FEBS Lett* 2010; **584**: 1481-1486 [PMID: 20219467 DOI: 10.1016/j.febslet.2010.02.063]

46 **Cheng SF**, Li L, Wang LM. miR-155 and miR-146b negatively regulates IL6 in Helicobacter pylori (cagA+) infected gastroduodenal ulcer. *Eur Rev Med Pharmacol Sci* 2015; **19**: 607-613 [PMID: 25753878]

47 **Teng GG**, Wang WH, Dai Y, Wang SJ, Chu YX, Li J. Let-7b is involved in the inflammation and immune responses associated with Helicobacter pylori infection by targeting Toll-like receptor 4. *PLoS One* 2013; **8**: e56709 [PMID: 23437218 DOI: 10.1371/journal.pone.0056709]

48 **Isomoto H**, Matsushima K, Inoue N, Hayashi T, Nakayama T, Kunizaki M, Hidaka S, Nakayama M, Hisatsune J, Nakashima M, Nagayasu T, Nakao K, Hirayama T. Interweaving microRNAs and proinflammatory cytokines in gastric mucosa with reference to *H. pylori* infection. *J Clin Immunol* 2012; **32**: 290-299 [PMID: 22161133 DOI: 10.1007/s10875-011-9626-3]

49 **Du Y**, Liu Z, Gu L, Zhou J, Zhu BD, Ji J, Deng D. Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo. *BMC Cancer* 2012; **12**: 249 [PMID: 22703336 DOI: 10.1186/1471-2407-12-249]

50 **Cheng Y**, Li Y, Liu D, Zhang R, Zhang J. miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway. *FEBS Lett* 2014; **588**: 3274-3281 [PMID: 25064845 DOI: 10.1016/j.febslet.2014.07.012]

51 **Steponaitiene R**, Kupcinskas J, Langner C, Balaguer F, Venclauskas L, Pauzas H, Tamelis A, Skieceviciene J, Kupcinskas L, Malfertheiner P, Link A. Epigenetic silencing of miR-137 is a frequent event in gastric carcinogenesis. *Mol Carcinog* 2015; Epub ahead of print [PMID: 25663388 DOI: 10.1002/mc.22287]

52 **Li Z**, Li D, Zhang G, Xiong J, Jie Z, Cheng H, Cao Y, Jiang M, Lin L, Le Z, Tan S, Zou W, Gong B, Lin S, Yang K. Methylation-associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer. *Am J Cancer Res* 2014; **4**: 648-662 [PMID: 25520857]

53 **Li Z**, Zhang G, Li D, Jie Z, Chen H, Xiong J, Liu Y, Cao Y, Jiang M, Le Z, Tan S. Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3. *Biochem Biophys Res Commun* 2015; **456**: 344-350 [PMID: 25475733 DOI: 10.1016/j.bbrc.2014.11.083]

54 **Li Y**, Xu Z, Li B, Zhang Z, Luo H, Wang Y, Lu Z, Wu X. Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG island hypermethylation in gastric cancer in vitro and in vivo. *Int J Oncol* 2014; **45**: 2576-2586 [PMID: 25270964 DOI: 10.3892/ijo.2014.2667]

55 **Li Z**, Lei H, Luo M, Wang Y, Dong L, Ma Y, Liu C, Song W, Wang F, Zhang J, Shen J, Yu J. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. *Gastric Cancer* 2015; **18**: 43-54 [PMID: 24481854 DOI: 10.1007/s10120-014-0340-8]

56 **Lei H**, Zou D, Li Z, Luo M, Dong L, Wang B, Yin H, Ma Y, Liu C, Wang F, Zhang J, Yu J, Li Y. MicroRNA-219-2-3p functions as a tumor suppressor in gastric cancer and is regulated by DNA methylation. *PLoS One* 2013; **8**: e60369 [PMID: 23637748 DOI: 10.1371/journal.pone.0060369]

57 **Xu L**, Wang F, Xu XF, Mo WH, Xia YJ, Wan R, Wang XP, Guo CY. Down-regulation of miR-212 expression by DNA hypermethylation in human gastric cancer cells. *Med Oncol* 2011; **28** Suppl 1: S189-S196 [PMID: 21053104 DOI: 10.1007/s12032-010-9691-0]

58 **Kim JG**, Kim TO, Bae JH, Shim JW, Kang MJ, Yang K, Ting AH, Yi JM. Epigenetically regulated MIR941 and MIR1247 target gastric cancer cell growth and migration. *Epigenetics* 2014; **9**: 1018-1030 [PMID: 24785261 DOI: 10.4161/epi.29007]

59 **Wu Q**, Yang Z, Xia L, Nie Y, Wu K, Shi Y, Fan D. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters. *Oncotarget* 2014; **5**: 11552-11563 [PMID: 25344911]

60 **Wu H**, Huang M, Lu M, Zhu W, Shu Y, Cao P, Liu P. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. *Cancer Chemother Pharmacol* 2013; **71**: 1159-1171 [PMID: 23423488 DOI: 10.1007/s00280-013-2108-y]

61 **Zuo J**, Xia J, Ju F, Yan J, Zhu A, Jin S, Shan T, Zhou H. MicroRNA-148a can regulate runt-related transcription factor 3 gene expression via modulation of DNA methyltransferase 1 in gastric cancer. *Mol Cells* 2013; **35**: 313-319 [PMID: 23549984 DOI: 10.1007/s10059-013-2314-9]

62 **Liu F**, Kong X, Lv L, Gao J. TGF-β1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes. *Cancer Lett* 2015; **359**: 288-298 [PMID: 25633840 DOI: 10.1016/j.canlet.2015.01.030]

63 **Brockhausen J**, Tay SS, Grzelak CA, Bertolino P, Bowen DG, d'Avigdor WM, Teoh N, Pok S, Shackel N, Gamble JR, Vadas M, McCaughan GW. miR-181a mediates TGF-β-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. *Liver Int* 2015; **35**: 240-253 [PMID: 24576072 DOI: 10.1111/liv.12517]

64 **Ding X**, Park SI, McCauley LK, Wang CY. Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. *J Biol Chem* 2013; **288**: 10241-10253 [PMID: 23447531 DOI: 10.1074/jbc.M112.443655]

65 **Zhou H**, Wang K, Hu Z, Wen J. TGF-β1 alters microRNA profile in human gastric cancer cells. *Chin J Cancer Res* 2013; **25**: 102-111 [PMID: 23372348 DOI: 10.3978/j.issn.1000-9604.2013.01.09]

66 **Wu DW**, Hsu NY, Wang YC, Lee MC, Cheng YW, Chen CY, Lee H. c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. *Oncogene* 2015; **34**: 2072-2082 [PMID: 24909176 DOI: 10.1038/onc.2014.152]

67 **Wang X**, Zhao X, Gao P, Wu M. c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. *Sci Rep* 2013; **3**: 1942 [PMID: 23735886 DOI: 10.1038/srep01942]

68 **Kim HR**, Roe JS, Lee JE, Hwang IY, Cho EJ, Youn HD. A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. *Biochem Biophys Res Commun* 2012; **418**: 682-688 [PMID: 22301190 DOI: 10.1016/j.bbrc.2012.01.077]

69 **Seok JK**, Lee SH, Kim MJ, Lee YM. MicroRNA-382 induced by HIF-1α is an angiogenic miR targeting the tumor suppressor phosphatase and tensin homolog. *Nucleic Acids Res* 2014; **42**: 8062-8072 [PMID: 24914051 DOI: 10.1093/nar/gku515]

70 **Kinose Y**, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. *Oncotarget* 2015; **6**: 11342-11356 [PMID: 25839163]

71 **Osugi J**, Kimura Y, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Muto S, Okabe N, Matsumura Y, Hasegawa T, Yonechi A, Hoshino M, Higuchi M, Shio Y, Suzuki H, Gotoh M. Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma. *J Oncol* 2015; **2015**: 316745 [PMID: 25733977 DOI: 10.1155/2015/316745]

72 **Bartoszewska S**, Kochan K, Piotrowski A, Kamysz W, Ochocka RJ, Collawn JF, Bartoszewski R. The hypoxia-inducible miR-429 regulates hypoxia-inducible factor-1α expression in human endothelial cells through a negative feedback loop. *FASEB J* 2015; **29**: 1467-1479 [PMID: 25550463 DOI: 10.1096/fj.14-267054]

73 **Brock M**, Haider TJ, Vogel J, Gassmann M, Speich R, Trenkmann M, Ulrich S, Kohler M, Huber LC. The hypoxia-induced microRNA-130a controls pulmonary smooth muscle cell proliferation by directly targeting CDKN1A. *Int J Biochem Cell Biol* 2015; **61**: 129-137 [PMID: 25681685 DOI: 10.1016/j.biocel.2015.02.002]

74 **Rosenberg T**, Thomassen M, Jensen SS, Larsen MJ, Sørensen KP, Hermansen SK, Kruse TA, Kristensen BW. Acute hypoxia induces upregulation of microRNA-210 expression in glioblastoma spheroids. *CNS Oncol* 2015; **4**: 25-35 [PMID: 25586423 DOI: 10.2217/cns.14.48]

75 **Wang Y**, Liu C, Luo M, Zhang Z, Gong J, Li J, You L, Dong L, Su R, Lin H, Ma Y, Wang F, Wang Y, Chen J, Zhang J, Jia H, Kong Y, Yu J. Chemotherapy-Induced miRNA-29c/Catenin-δ Signaling Suppresses Metastasis in Gastric Cancer. *Cancer Res* 2015; **75**: 1332-1344 [PMID: 25634213 DOI: 10.1158/0008-5472.CAN-14-0787]

76 **Shang Y**, Zhang Z, Liu Z, Feng B, Ren G, Li K, Zhou L, Sun Y, Li M, Zhou J, An Y, Wu K, Nie Y, Fan D. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. *Oncogene* 2014; **33**: 3267-3276 [PMID: 23893241 DOI: 10.1038/onc.2013.297]

77 **Yang M**, Shan X, Zhou X, Qiu T, Zhu W, Ding Y, Shu Y, Liu P. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. *Anticancer Agents Med Chem* 2014; **14**: 884-891 [PMID: 24875127 DOI: 10.2174/1871520614666140528161318]

78 **Wang T**, Ge G, Ding Y, Zhou X, Huang Z, Zhu W, Shu Y, Liu P. MiR-503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2. *Chin Med J (Engl)* 2014; **127**: 2357-2362 [PMID: 24931256]

79 **Wang F**, Li T, Zhang B, Li H, Wu Q, Yang L, Nie Y, Wu K, Shi Y, Fan D. MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. *Biochem Biophys Res Commun* 2013; **434**: 688-694 [PMID: 23603256 DOI: 10.1016/j.bbrc.2013.04.010]

80 **Yang SM**, Huang C, Li XF, Yu MZ, He Y, Li J. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. *Toxicology* 2013; **306**: 162-168 [PMID: 23466500 DOI: 10.1016/j.tox.2013.02.014]

81 **Zhang Y**, Lu Q, Cai X. MicroRNA-106a induces multidrug resistance in gastric cancer by targeting RUNX3. *FEBS Lett* 2013; **587**: 3069-3075 [PMID: 23932924 DOI: 10.1016/j.febslet.2013.06.058]

82 **Zhou X**, Jin W, Jia H, Yan J, Zhang G. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7. *J Exp Clin Cancer Res* 2015; **34**: 28 [PMID: 25888377 DOI: 10.1186/s13046-015-0145-6]

83 **Tang X**, Zheng D, Hu P, Zeng Z, Li M, Tucker L, Monahan R, Resnick MB, Liu M, Ramratnam B. Glycogen synthase kinase 3 beta inhibits microRNA-183-96-182 cluster via the β-Catenin/TCF/LEF-1 pathway in gastric cancer cells. *Nucleic Acids Res* 2014; **42**: 2988-2998 [PMID: 24335145 DOI: 10.1093/nar/gkt1275]

84 **Iio A**, Takagi T, Miki K, Naoe T, Nakayama A, Akao Y. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells. *Biochim Biophys Acta* 2013; **1829**: 1102-1110 [PMID: 23932921 DOI: 10.1016/j.bbagrm.2013.07.010]

85 **Wang Y**, Gao S, Liu G, Jia R, Fan D, Feng X. Microarray expression profile analysis of long non-coding RNAs in human gastric cardiac adenocarcinoma. *Cell Physiol Biochem* 2014; **33**: 1225-1238 [PMID: 24751403 DOI: 10.1159/000358692]

86 **Ding J**, Li D, Gong M, Wang J, Huang X, Wu T, Wang C. Expression and clinical significance of the long non-coding RNA PVT1 in human gastric cancer. *Onco Targets Ther* 2014; **7**: 1625-1630 [PMID: 25258543 DOI: 10.2147/OTT.S68854]

87 **Okugawa Y**, Toiyama Y, Hur K, Toden S, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Kusunoki M, Boland CR, Goel A. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. *Carcinogenesis* 2014; **35**: 2731-2739 [PMID: 25280565 DOI: 10.1093/carcin/bgu200]

88 **Pan W**, Liu L, Wei J, Ge Y, Zhang J, Chen H, Zhou L, Yuan Q, Zhou C, Yang M. A functional lncRNA HOTAIR genetic variant contributes to gastric cancer susceptibility. *Mol Carcinog* 2015; Epub ahead of print [PMID: 25640751 DOI: 10.1002/mc.22261]

89 **Liu XH**, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, De W, Wang KM, Wang ZX. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. *Mol Cancer* 2014; **13**: 92 [PMID: 24775712 DOI: 10.1186/1476-4598-13-92]

90 **Zhang EB**, Han L, Yin DD, Kong R, De W, Chen J. c-Myc-induced, long, noncoding H19 affects cell proliferation and predicts a poor prognosis in patients with gastric cancer. *Med Oncol* 2014; **31**: 914 [PMID: 24671855 DOI: 10.1007/s12032-014-0914-7]

91 **Zhuang M**, Gao W, Xu J, Wang P, Shu Y. The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. *Biochem Biophys Res Commun* 2014; **448**: 315-322 [PMID: 24388988 DOI: 10.1016/j.bbrc.2013.12.126]

92 **Wang J**, Su L, Chen X, Li P, Cai Q, Yu B, Liu B, Wu W, Zhu Z. MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF. *Biomed Pharmacother* 2014; **68**: 557-564 [PMID: 24857172 DOI: 10.1016/j.biopha.2014.04.007]

93 **Chen F**, Tian Y, Pang EJ, Wang Y, Li L. MALAT2-activated long noncoding RNA indicates a biomarker of poor prognosis in gastric cancer. *Cancer Gene Ther* 2015; Epub ahead of print [PMID: 25721209 DOI: 10.1038/cgt.2015.6]

94 **Qi P**, Xu MD, Shen XH, Ni SJ, Huang D, Tan C, Weng WW, Sheng WQ, Zhou XY, Du X. Reciprocal repression between TUSC7 and miR-23b in gastric cancer. *Int J Cancer* 2015; **137**: 1269-1278 [PMID: 25765901 DOI: 10.1002/ijc.29516]

95 **Zhou B**, Jing XY, Wu JQ, Xi HF, Lu GJ. Down-regulation of long non-coding RNA LET is associated with poor prognosis in gastric cancer. *Int J Clin Exp Pathol* 2014; **7**: 8893-8898 [PMID: 25674261]

96 **Xu TP**, Huang MD, Xia R, Liu XX, Sun M, Yin L, Chen WM, Han L, Zhang EB, Kong R, De W, Shu YQ. Decreased expression of the long non-coding RNA FENDRR is associated with poor prognosis in gastric cancer and FENDRR regulates gastric cancer cell metastasis by affecting fibronectin1 expression. *J Hematol Oncol* 2014; **7**: 63 [PMID: 25167886 DOI: 10.1186/s13045-014-0063-7]

97 **Shao Y**, Chen H, Jiang X, Chen S, Li P, Ye M, Li Q, Sun W, Guo J. Low expression of lncRNA-HMlincRNA717 in human gastric cancer and its clinical significances. *Tumour Biol* 2014; **35**: 9591-9595 [PMID: 24961350 DOI: 10.1007/s13277-014-2243-z]

98 **Liu Z**, Shao Y, Tan L, Shi H, Chen S, Guo J. Clinical significance of the low expression of FER1L4 in gastric cancer patients. *Tumour Biol* 2014; **35**: 9613-9617 [PMID: 24961353 DOI: 10.1007/s13277-014-2259-4]

99 **Sun M**, Jin FY, Xia R, Kong R, Li JH, Xu TP, Liu YW, Zhang EB, Liu XH, De W. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. *BMC Cancer* 2014; **14**: 319 [PMID: 24884417 DOI: 10.1186/1471-2407-14-319]

100 **Sun M**, Xia R, Jin F, Xu T, Liu Z, De W, Liu X. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. *Tumour Biol* 2014; **35**: 1065-1073 [PMID: 24006224 DOI: 10.1007/s13277-013-1142-z]

101 **Han Y**, Ye J, Wu D, Wu P, Chen Z, Chen J, Gao S, Huang J. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. *BMC Cancer* 2014; **14**: 932 [PMID: 25496320 DOI: 10.1186/1471-2407-14-932]

102 **Zhou X**, Xia Y, Li L, Zhang G. MiR-101 inhibits cell growth and tumorigenesis of Helicobacter pylori related gastric cancer by repression of SOCS2. *Cancer Biol Ther* 2015; **16**: 160-169 [PMID: 25561270 DOI: 10.4161/15384047.2014.987523]

103 **Zheng X**, Dong J, Gong T, Zhang Z, Wang Y, Li Y, Shang Y, Li K, Ren G, Feng B, Li J, Tian Q, Tang S, Sun L, Li M, Zhang H, Fan D. MicroRNA library-based functional screening identified miR-137 as a suppresser of gastric cancer cell proliferation. *J Cancer Res Clin Oncol* 2015; **141**: 785-795 [PMID: 25342326 DOI: 10.1007/s00432-014-1847-4]

104 **Li R**, Yuan W, Mei W, Yang K, Chen Z. MicroRNA 520d-3p inhibits gastric cancer cell proliferation, migration, and invasion by downregulating EphA2 expression. *Mol Cell Biochem* 2014; **396**: 295-305 [PMID: 25063221 DOI: 10.1007/s11010-014-2164-6]

105 **Guo SL**, Ye H, Teng Y, Wang YL, Yang G, Li XB, Zhang C, Yang X, Yang ZZ, Yang X. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. *Nat Commun* 2013; **4**: 2544 [PMID: 24149576 DOI: 10.1038/ncomms3544]

106 **He J**, Hua J, Ding N, Xu S, Sun R, Zhou G, Xie X, Wang J. Modulation of microRNAs by ionizing radiation in human gastric cancer. *Oncol Rep* 2014; **32**: 787-793 [PMID: 24919435 DOI: 10.3892/or.2014.3246]

107 **Peng WZ**, Ma R, Wang F, Yu J, Liu ZB. Role of miR-191/425 cluster in tumorigenesis and diagnosis of gastric cancer. *Int J Mol Sci* 2014; **15**: 4031-4048 [PMID: 24603541 DOI: 10.3390/ijms15034031]

108 **Chen L**, Lü MH, Zhang D, Hao NB, Fan YH, Wu YY, Wang SM, Xie R, Fang DC, Zhang H, Hu CJ, Yang SM. miR-1207-5p and miR-1266 suppress gastric cancer growth and invasion by targeting telomerase reverse transcriptase. *Cell Death Dis* 2014; **5**: e1034 [PMID: 24481448 DOI: 10.1038/cddis.2013.553]

109 **Jiping Z**, Ming F, Lixiang W, Xiuming L, Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C, Jihui J. MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. *J Cell Biochem* 2013; **114**: 2666-2672 [PMID: 23794145 DOI: 10.1002/jcb.24613]

110 **Wang M**, Gu H, Qian H, Zhu W, Zhao C, Zhang X, Tao Y, Zhang L, Xu W. miR-17-5p/20a are important markers for gastric cancer and murine double minute 2 participates in their functional regulation. *Eur J Cancer* 2013; **49**: 2010-2021 [PMID: 23333058 DOI: 10.1016/j.ejca.2012.12.017]

111 **Wang GJ**, Liu GH, Ye YW, Fu Y, Zhang XF. The role of microRNA-1274a in the tumorigenesis of gastric cancer: accelerating cancer cell proliferation and migration via directly targeting FOXO4. *Biochem Biophys Res Commun* 2015; **459**: 629-635 [PMID: 25753202 DOI: 10.1016/j.bbrc.2015.02.160]

112 **Shen X**, Si Y, Yang Z, Wang Q, Yuan J, Zhang X. MicroRNA-542-3p suppresses cell growth of gastric cancer cells via targeting oncogene astrocyte-elevated gene-1. *Med Oncol* 2015; **32**: 361 [PMID: 25432696 DOI: 10.1007/s12032-014-0361-5]

113 **Peng Y**, Guo JJ, Liu YM, Wu XL. MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. *Biosci Rep* 2014; **34**: [PMID: 24837198 DOI: 10.1042/BSR20140020]

114 **Peng Y**, Liu YM, Li LC, Wang LL, Wu XL. MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression. *PLoS One* 2014; **9**: e94422 [PMID: 24736504 DOI: 10.1371/journal.pone.0094422]

115 **Guo B**, Liu L, Yao J, Ma R, Chang D, Li Z, Song T, Huang C. miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a. *Mol Cancer Res* 2014; **12**: 313-321 [PMID: 24375644 DOI: 10.1158/1541-7786.MCR-13-0507]

116 **Sha M**, Ye J, Zhang LX, Luan ZY, Chen YB, Huang JX. Celastrol induces apoptosis of gastric cancer cells by miR-21 inhibiting PI3K/Akt-NF-κB signaling pathway. *Pharmacology* 2014; **93**: 39-46 [PMID: 24434352 DOI: 10.1159/000357683]

117 **Xia J**, Wu Z, Yu C, He W, Zheng H, He Y, Jian W, Chen L, Zhang L, Li W. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. *J Pathol* 2012; **227**: 470-480 [PMID: 22450659 DOI: 10.1002/path.4030]

118 **Liu Z**, Zhu J, Cao H, Ren H, Fang X. miR-10b promotes cell invasion through RhoC-AKT signaling pathway by targeting HOXD10 in gastric cancer. *Int J Oncol* 2012; **40**: 1553-1560 [PMID: 22293682 DOI: 10.3892/ijo.2012.1342]

119 **Chen H**, Li L, Wang S, Lei Y, Ge Q, Lv N, Zhou X, Chen C. Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. *Oncotarget* 2014; **5**: 11873-11885 [PMID: 25428912]

120 **Zhang H**, Cheng Y, Jia C, Yu S, Xiao Y, Chen J. MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability. *Med Oncol* 2015; **32**: 342 [PMID: 25428377 DOI: 10.1007/s12032-014-0342-8]

121 **Kang W**, Tong JH, Lung RW, Dong Y, Yang W, Pan Y, Lau KM, Yu J, Cheng AS, To KF. let-7b/g silencing activates AKT signaling to promote gastric carcinogenesis. *J Transl Med* 2014; **12**: 281 [PMID: 25288334 DOI: 10.1186/s12967-014-0281-3]

122 **Li X**, Li H, Zhang R, Liu J, Liu J. MicroRNA-449a inhibits proliferation and induces apoptosis by directly repressing E2F3 in gastric cancer. *Cell Physiol Biochem* 2015; **35**: 2033-2042 [PMID: 25871967 DOI: 10.1159/000374010]

123 **Xu XC**, Zhang YH, Zhang WB, Li T, Gao H, Wang YH. MicroRNA-133a functions as a tumor suppressor in gastric cancer. *J Biol Regul Homeost Agents* 2014; **28**: 615-624 [PMID: 25620172]

124 **Lai C**, Chen Z, Li R. MicroRNA-133a inhibits proliferation and invasion, and induces apoptosis in gastric carcinoma cells via targeting fascin actin-bundling protein 1. *Mol Med Rep* 2015; **12**: 1473-1478 [PMID: 25815687 DOI: 10.3892/mmr.2015.3545]

125 **Liu H**, Li P, Li B, Sun P, Zhang J, Wang B, Jia B. RKIP suppresses gastric cancer cell proliferation and invasion and enhances apoptosis regulated by microRNA-224. *Tumour Biol* 2014; **35**: 10095-10103 [PMID: 25017365 DOI: 10.1007/s13277-014-2303-4]

126 **Li P**, Chen X, Su L, Li C, Zhi Q, Yu B, Sheng H, Wang J, Feng R, Cai Q, Li J, Yu Y, Yan M, Liu B, Zhu Z. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. *PLoS One* 2013; **8**: e66782 [PMID: 23826132 DOI: 10.1371/journal.pone.0066782]

127 **Wu XL**, Cheng B, Li PY, Huang HJ, Zhao Q, Dan ZL, Tian DA, Zhang P. MicroRNA-143 suppresses gastric cancer cell growth and induces apoptosis by targeting COX-2. *World J Gastroenterol* 2013; **19**: 7758-7765 [PMID: 24616567 DOI: 10.3748/wjg.v19.i43.7758]

128 **Jiang B**, Li Z, Zhang W, Wang H, Zhi X, Feng J, Chen Z, Zhu Y, Yang L, Xu H, Xu Z. miR-874 Inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. *J Gastroenterol* 2014; **49**: 1011-1025 [PMID: 23800944 DOI: 10.1007/s00535-013-0851-9]

129 **Hu J**, Fang Y, Cao Y, Qin R, Chen Q. miR-449a Regulates proliferation and chemosensitivity to cisplatin by targeting cyclin D1 and BCL2 in SGC7901 cells. *Dig Dis Sci* 2014; **59**: 336-345 [PMID: 24248414 DOI: 10.1007/s10620-013-2923-3]

130 **Wei B**, Song Y, Zhang Y, Hu M. microRNA-449a functions as a tumor-suppressor in gastric adenocarcinoma by targeting Bcl-2. *Oncol Lett* 2013; **6**: 1713-1718 [PMID: 24260067 DOI: 10.3892/ol.2013.1609]

131 **Gu W**, Gao T, Shen J, Sun Y, Zheng X, Wang J, Ma J, Hu XY, Li J, Hu MJ. MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4. *Int J Clin Exp Med* 2014; **7**: 2519-2529 [PMID: 25356105]

132 **Feng X**, Wang Y, Ma Z, Yang R, Liang S, Zhang M, Song S, Li S, Liu G, Fan D, Gao S. MicroRNA-645, up-regulated in human adencarcinoma of gastric esophageal junction, inhibits apoptosis by targeting tumor suppressor IFIT2. *BMC Cancer* 2014; **14**: 633 [PMID: 25174799 DOI: 10.1186/1471-2407-14-633]

133 **Zhang X**, Nie Y, Li X, Wu G, Huang Q, Cao J, Du Y, Li J, Deng R, Huang D, Chen B, Li S, Wei B. MicroRNA-181a functions as an oncomir in gastric cancer by targeting the tumour suppressor gene ATM. *Pathol Oncol Res* 2014; **20**: 381-389 [PMID: 24531888 DOI: 10.1007/s12253-013-9707-0]

134 **Liu N**, Zuo C, Wang X, Chen T, Yang D, Wang J, Zhu H. miR-942 decreases TRAIL-induced apoptosis through ISG12a downregulation and is regulated by AKT. *Oncotarget* 2014; **5**: 4959-4971 [PMID: 24970806]

135 **Ma J**, Liu J, Wang Z, Gu X, Fan Y, Zhang W, Xu L, Zhang J, Cai D. NF-kappaB-dependent microRNA-425 upregulation promotes gastric cancer cell growth by targeting PTEN upon IL-1β induction. *Mol Cancer* 2014; **13**: 40 [PMID: 24571667 DOI: 10.1186/1476-4598-13-40]

136 **Xia JT**, Chen LZ, Jian WH, Wang KB, Yang YZ, He WL, He YL, Chen D, Li W. MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling. *J Transl Med* 2014; **12**: 33 [PMID: 24495516 DOI: 10.1186/1479-5876-12-33]

137 **Zhang L**, Ding Y, Yuan Z, Liu J, Sun J, Lei F, Wu S, Li S, Zhang D. MicroRNA-500 sustains nuclear factor-κB activation and induces gastric cancer cell proliferation and resistance to apoptosis. *Oncotarget* 2015; **6**: 2483-2495 [PMID: 25595906]

138 **Chen Z**, Zhang L, Xia L, Jin Y, Wu Q, Guo H, Shang X, Dou J, Wu K, Nie Y, Fan D. Genomic analysis of drug resistant gastric cancer cell lines by combining mRNA and microRNA expression profiling. *Cancer Lett* 2014; **350**: 43-51 [PMID: 24759738 DOI: 10.1016/j.canlet.2014.04.010]

139 **Li Q**, Wang JX, He YQ, Feng C, Zhang XJ, Sheng JQ, Li PF. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. *Cell Death Dis* 2014; **5**: e1197 [PMID: 24763054 DOI: 10.1038/cddis.2014.148]

140 **Zhang XL**, Shi HJ, Wang JP, Tang HS, Wu YB, Fang ZY, Cui SZ, Wang LT. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. *World J Gastroenterol* 2014; **20**: 11347-11355 [PMID: 25170221 DOI: 10.3748/wjg.v20.i32.11347]

141 **Chang L**, Guo F, Wang Y, Lv Y, Huo B, Wang L, Liu W. MicroRNA-200c regulates the sensitivity of chemotherapy of gastric cancer SGC7901/DDP cells by directly targeting RhoE. *Pathol Oncol Res* 2014; **20**: 93-98 [PMID: 23821457 DOI: 10.1007/s12253-013-9664-7]

142 **Gu W**, Gao T, Sun Y, Zheng X, Wang J, Ma J, Hu X, Li J, Hu M. LncRNA expression profile reveals the potential role of lncRNAs in gastric carcinogenesis. *Cancer Biomark* 2015; Epub ahead of print [PMID: 25769450 DOI: 10.3233/CBM-150460]

143 **Song H**, Sun W, Ye G, Ding X, Liu Z, Zhang S, Xia T, Xiao B, Xi Y, Guo J. Long non-coding RNA expression profile in human gastric cancer and its clinical significances. *J Transl Med* 2013; **11**: 225 [PMID: 24063685 DOI: 10.1186/1479-5876-11-225]

144 **Zhang Y**, Ma M, Liu W, Ding W, Yu H. Enhanced expression of long noncoding RNA CARLo-5 is associated with the development of gastric cancer. *Int J Clin Exp Pathol* 2014; **7**: 8471-8479 [PMID: 25674211]

145 **Wang CY**, Hua L, Yao KH, Chen JT, Zhang JJ, Hu JH. Long non-coding RNA CCAT2 is up-regulated in gastric cancer and associated with poor prognosis. *Int J Clin Exp Pathol* 2015; **8**: 779-785 [PMID: 25755774]

146 **Mei D**, Song H, Wang K, Lou Y, Sun W, Liu Z, Ding X, Guo J. Up-regulation of SUMO1 pseudogene 3 (SUMO1P3) in gastric cancer and its clinical association. *Med Oncol* 2013; **30**: 709 [PMID: 23996296 DOI: 10.1007/s12032-013-0709-2]

147 **Pang Q**, Ge J, Shao Y, Sun W, Song H, Xia T, Xiao B, Guo J. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. *Tumour Biol* 2014; **35**: 5441-5447 [PMID: 24523021 DOI: 10.1007/s13277-014-1709-3]

148 **Lin X**, Yang M, Xia T, Guo J. Increased expression of long noncoding RNA ABHD11-AS1 in gastric cancer and its clinical significance. *Med Oncol* 2014; **31**: 42 [PMID: 24984296]

149 **Chen X**, Sun J, Song Y, Gao P, Zhao J, Huang X, Liu B, Xu H, Wang Z. The novel long noncoding RNA AC138128.1 may be a predictive biomarker in gastric cancer. *Med Oncol* 2014; **31**: 262 [PMID: 25260808 DOI: 10.1007/s12032-014-0262-7]

150 **Mizrahi I**, Mazeh H, Grinbaum R, Beglaibter N, Wilschanski M, Pavlov V, Adileh M, Stojadinovic A, Avital I, Gure AO, Halle D, Nissan A. Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach. *J Cancer* 2015; **6**: 105-110 [PMID: 25561974 DOI: 10.7150/jca.10568]

151 **Chen WM**, Huang MD, Kong R, Xu TP, Zhang EB, Xia R, Sun M, De W, Shu YQ. Antisense Long Noncoding RNA HIF1A-AS2 Is Upregulated in Gastric Cancer and Associated with Poor Prognosis. *Dig Dis Sci* 2015; **60**: 1655-1662 [PMID: 25686741 DOI: 10.1007/s10620-015-3524-0]

152 **Dong L**, Qi P, Xu MD, Ni SJ, Huang D, Xu QH, Weng WW, Tan C, Sheng WQ, Zhou XY, Du X. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. *Int J Cancer* 2015; Epub ahead of print [PMID: 25694351 DOI: 10.1002/ijc.29484]

153 **Shao Y**, Ye M, Jiang X, Sun W, Ding X, Liu Z, Ye G, Zhang X, Xiao B, Guo J. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer. *Cancer* 2014; **120**: 3320-3328 [PMID: 24986041 DOI: 10.1002/cncr.28882]

154 **Arita T**, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Circulating long non-coding RNAs in plasma of patients with gastric cancer. *Anticancer Res* 2013; **33**: 3185-3193 [PMID: 23898077]

155 **Yang F**, Xue X, Bi J, Zheng L, Zhi K, Gu Y, Fang G. Long noncoding RNA CCAT1, which could be activated by c-Myc, promotes the progression of gastric carcinoma. *J Cancer Res Clin Oncol* 2013; **139**: 437-445 [PMID: 23143645 DOI: 10.1007/s00432-012-1324-x]

156 **Peng W**, Wu G, Fan H, Wu J, Feng J. Long noncoding RNA SPRY4-IT1 predicts poor patient prognosis and promotes tumorigenesis in gastric cancer. *Tumour Biol* 2015; Epub ahead of print [PMID: 25835973 DOI: 10.1007/s12035-015-9142-1]

157 **Yang F**, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y, Fang G. Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. *FEBS J* 2014; **281**: 802-813 [PMID: 24397586 DOI: 10.1111/febs.12625]

158 **Zhao Y**, Guo Q, Chen J, Hu J, Wang S, Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. *Oncol Rep* 2014; **31**: 358-364 [PMID: 24247585 DOI: 10.3892/or.2013.2850]

159 **Wang Y**, Zhang D, Wu K, Zhao Q, Nie Y, Fan D. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. *Mol Cell Biol* 2014; **34**: 3182-3193 [PMID: 24958102 DOI: 10.1128/MCB.01580-13]

160 **Yang F**, Bi J, Xue X, Zheng L, Zhi K, Hua J, Fang G. Up-regulated long non-coding RNA H19 contributes to proliferation of gastric cancer cells. *FEBS J* 2012; **279**: 3159-3165 [PMID: 22776265 DOI: 10.1111/j.1742-4658.2012.08694.x]

161 **Zhang EB**, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W, Chen Jf. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a. *Oncotarget* 2014; **5**: 2276-2292 [PMID: 24810364]

162 **Xu C**, Shao Y, Xia T, Yang Y, Dai J, Luo L, Zhang X, Sun W, Song H, Xiao B, Guo J. lncRNA-AC130710 targeting by miR-129-5p is upregulated in gastric cancer and associates with poor prognosis. *Tumour Biol* 2014; **35**: 9701-9706 [PMID: 24969565 DOI: 10.1007/s13277-014-2274-5]

163 **Zhang Z**, Liu S, Shi R, Zhao G. miR-27 promotes human gastric cancer cell metastasis by inducing epithelial-to-mesenchymal transition. *Cancer Genet* 2011; **204**: 486-491 [PMID: 22018270 DOI: 10.1016/j.cancergen.2011.07.004]

164 **Yang Q**, Jie Z, Ye S, Li Z, Han Z, Wu J, Yang C, Jiang Y. Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility. *Oncogene* 2014; **33**: 193-202 [PMID: 23246964 DOI: 10.1038/onc.2012.569]

165 **Li L**, Zhou L, Li Y, Lin S, Tomuleasa C. MicroRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog. *J BUON* 2014; **19**: 228-236 [PMID: 24659669]

166 **Uozaki H**, Morita S, Kumagai A, Aso T, Soejima Y, Takahashi Y, Fukusato T. Stromal miR-21 is more important than miR-21 of tumour cells for the progression of gastric cancer. *Histopathology* 2014; **65**: 775-783 [PMID: 25041158 DOI: 10.1111/his.12491]

167 **Zhang BG**, Li JF, Yu BQ, Zhu ZG, Liu BY, Yan M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. *Oncol Rep* 2012; **27**: 1019-1026 [PMID: 22267008 DOI: 10.3892/or.2012.1645]

168 **Xu Y**, Sun J, Xu J, Li Q, Guo Y, Zhang Q. miR-21 Is a Promising Novel Biomarker for Lymph Node Metastasis in Patients with Gastric Cancer. *Gastroenterol Res Pract* 2012; **2012**: 640168 [PMID: 22792096 DOI: 10.1155/2012/640168]

169 **Luo F**, Ji J, Liu Y, Xu Y, Zheng G, Jing J, Wang B, Xu W, Shi L, Lu X, Liu Q. MicroRNA-21, up-regulated by arsenite, directs the epithelial-mesenchymal transition and enhances the invasive potential of transformed human bronchial epithelial cells by targeting PDCD4. *Toxicol Lett* 2014; **232**: 301-309 [PMID: 25445583 DOI: 10.1016/j.toxlet.2014.11.001]

170 **Yu D**, Shin HS, Lee YS, Lee YC. miR-106b modulates cancer stem cell characteristics through TGF-β/Smad signaling in CD44-positive gastric cancer cells. *Lab Invest* 2014; **94**: 1370-1381 [PMID: 25286029 DOI: 10.1038/labinvest.2014.125]

171 **Yu P**, Fan S, Huang L, Yang L, Du Y. MIR210 as a potential molecular target to block invasion and metastasis of gastric cancer. *Med Hypotheses* 2015; **84**: 209-212 [PMID: 25618442 DOI: 10.1016/j.mehy.2014.12.024]

172 **Tsai MM**, Wang CS, Tsai CY, Chen CY, Chi HC, Tseng YH, Chung PJ, Lin YH, Chung IH, Chen CY, Lin KH. MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. *Cancer Lett* 2014; **351**: 222-231 [PMID: 24933454 DOI: 10.1016/j.canlet.2014.06.004]

173 **Wu Q**, Yang Z, An Y, Hu H, Yin J, Zhang P, Nie Y, Wu K, Shi Y, Fan D. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. *Cell Death Dis* 2014; **5**: e1144 [PMID: 24675462 DOI: 10.1038/cddis.2014.110]

174 **He XJ**, Ma YY, Yu S, Jiang XT, Lu YD, Tao L, Wang HP, Hu ZM, Tao HQ. Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. *BMC Cancer* 2014; **14**: 218 [PMID: 24655788 DOI: 10.1186/1471-2407-14-218]

175 **Davalos V**, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. *Oncogene* 2012; **31**: 2062-2074 [PMID: 21874049 DOI: 10.1038/onc.2011.383]

176 **Song F**, Yang D, Liu B, Guo Y, Zheng H, Li L, Wang T, Yu J, Zhao Y, Niu R, Liang H, Winkler H, Zhang W, Hao X, Chen K. Integrated microRNA network analyses identify a poor-prognosis subtype of gastric cancer characterized by the miR-200 family. *Clin Cancer Res* 2014; **20**: 878-889 [PMID: 24352645 DOI: 10.1158/1078-0432.CCR-13-1844]

177 **Wan X**, Ding X, Chen S, Song H, Jiang H, Fang Y, Li P, Guo J. The functional sites of miRNAs and lncRNAs in gastric carcinogenesis. *Tumour Biol* 2015; **36**: 521-532 [PMID: 25636450 DOI: 10.1007/s13277-015-3136-5]

178 **Zhang D**, Xiao YF, Zhang JW, Xie R, Hu CJ, Tang B, Wang SM, Wu YY, Hao NB, Yang SM. miR-1182 attenuates gastric cancer proliferation and metastasis by targeting the open reading frame of hTERT. *Cancer Lett* 2015; **360**: 151-159 [PMID: 25662441 DOI: 10.1016/j.canlet.2015.01.044]

179 **Kogo R**, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. *Clin Cancer Res* 2011; **17**: 4277-4284 [PMID: 21632853 DOI: 10.1158/1078-0432.CCR-10-2866]

180 **Zhou L**, Zhao X, Han Y, Lu Y, Shang Y, Liu C, Li T, Jin Z, Fan D, Wu K. Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis. *FASEB J* 2013; **27**: 4929-4939 [PMID: 23982143 DOI: 10.1096/fj.13-233387]

181 **Ishimoto T**, Izumi D, Watanabe M, Yoshida N, Hidaka K, Miyake K, Sugihara H, Sawayama H, Imamura Y, Iwatsuki M, Iwagami S, Baba Y, Horlad H, Komohara Y, Takeya M, Baba H. Chronic inflammation with Helicobacter pylori infection is implicated in CD44 overexpression through miR-328 suppression in the gastric mucosa. *J Gastroenterol* 2015; **50**: 751-757 [PMID: 25479940 DOI: 10.1007/s00535-014-1019-y]

182 **Zhang ZZ**, Shen ZY, Shen YY, Zhao EH, Wang M, Wang CJ, Cao H, Xu J. HOTAIR Long Noncoding RNA Promotes Gastric Cancer Metastasis through Suppression of Poly r(C)-Binding Protein (PCBP) 1. *Mol Cancer Ther* 2015; **14**: 1162-1170 [PMID: 25612617 DOI: 10.1158/1535-7163.MCT-14-0695]

183 **Wang Y**, Liu X, Zhang H, Sun L, Zhou Y, Jin H, Zhang H, Zhang H, Liu J, Guo H, Nie Y, Wu K, Fan D, Zhang H, Liu L. Hypoxia-inducible lncRNA-AK058003 promotes gastric cancer metastasis by targeting γ-synuclein. *Neoplasia* 2014; **16**: 1094-1106 [PMID: 25499222 DOI: 10.1016/j.neo.2014.10.008]

184 **Hu Y**, Pan J, Wang Y, Li L, Huang Y. Long noncoding RNA linc-UBC1 is negative prognostic factor and exhibits tumor pro-oncogenic activity in gastric cancer. *Int J Clin Exp Pathol* 2015; **8**: 594-600 [PMID: 25755750]

185 **Yan Y**, Shen Z, Gao Z, Cao J, Yang Y, Wang B, Shen C, Mao S, Jiang K, Ye Y, Wang S. Long noncoding ribonucleic acid specific for distant metastasis of gastric cancer is associated with TRIM16 expression and facilitates tumor cell invasion in vitro. *J Gastroenterol Hepatol* 2015; **30**: 1367-1375 [PMID: 25866896 DOI: 10.1111/jgh.12976]

186 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

187 **Zhang X**, Tang J, Zhi X, Xie K, Wang W, Li Z, Zhu Y, Yang L, Xu H, Xu Z. miR-874 functions as a tumor suppressor by inhibiting angiogenesis through STAT3/VEGF-A pathway in gastric cancer. *Oncotarget* 2015; **6**: 1605-1617 [PMID: 25596740]

188 **Zheng Y**, Li S, Ding Y, Wang Q, Luo H, Shi Q, Hao Z, Xiao G, Tong S. The role of miR-18a in gastric cancer angiogenesis. *Hepatogastroenterology* 2013; **60**: 1809-1813 [PMID: 24624454]

189 **Zheng L**, Pu J, Qi T, Qi M, Li D, Xiang X, Huang K, Tong Q. miRNA-145 targets v-ets erythroblastosis virus E26 oncogene homolog 1 to suppress the invasion, metastasis, and angiogenesis of gastric cancer cells. *Mol Cancer Res* 2013; **11**: 182-193 [PMID: 23233482 DOI: 10.1158/1541-7786.MCR-12-0534]

190 **Michalik KM**, You X, Manavski Y, Doddaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S. Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. *Circ Res* 2014; **114**: 1389-1397 [PMID: 24602777 DOI: 10.1161/CIRCRESAHA.114.303265]

191 **Yuan SX**, Yang F, Yang Y, Tao QF, Zhang J, Huang G, Yang Y, Wang RY, Yang S, Huo XS, Zhang L, Wang F, Sun SH, Zhou WP. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. *Hepatology* 2012; **56**: 2231-2241 [PMID: 22706893 DOI: 10.1002/hep.25895]

192 **Chen G**, Tang Y, Wu JH, Liu FH. Role of microRNAs in diagnosis and treatment of the pathogenesis of gastric cancer. *Int J Clin Exp Med* 2014; **7**: 5947-5957 [PMID: 25664140]

193 **Zhu ED**, Li N, Li BS, Li W, Zhang WJ, Mao XH, Guo G, Zou QM, Xiao B. miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. *PLoS One* 2014; **9**: e106049 [PMID: 25170877 DOI: 10.1371/journal.pone.0106049]

194 **Xia J**, Guo X, Yan J, Deng K. The role of miR-148a in gastric cancer. *J Cancer Res Clin Oncol* 2014; **140**: 1451-1456 [PMID: 24659367]

195 **Guo B**, Li J, Liu L, Hou N, Chang D, Zhao L, Li Z, Song T, Huang C. Dysregulation of miRNAs and their potential as biomarkers for the diagnosis of gastric cancer. *Biomed Rep* 2013; **1**: 907-912 [PMID: 24649051 DOI: 10.3892/br.2013.175]

196 **Xu Y**, Jin J, Liu Y, Huang Z, Deng Y, You T, Zhou T, Si J, Zhuo W. Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2. *PLoS One* 2014; **9**: e99516 [PMID: 25055044 DOI: 10.1371/journal.pone.0099516]

197 **Ye F**, Tang C, Shi W, Qian J, Xiao S, Gu M, Dang Y, Liu J, Chen Y, Shi R, Zhang G. A MDM2-dependent positive-feedback loop is involved in inhibition of miR-375 and miR-106b induced by Helicobacter pylori lipopolysaccharide. *Int J Cancer* 2015; **136**: 2120-2131 [PMID: 25307786 DOI: 10.1002/ijc.29268]

198 **Li PF**, Chen SC, Xia T, Jiang XM, Shao YF, Xiao BX, Guo JM. Non-coding RNAs and gastric cancer. *World J Gastroenterol* 2014; **20**: 5411-5419 [PMID: 24833871 DOI: 10.3748/wjg.v20.i18.5411]

199 **Cui L**, Zhang X, Ye G, Zheng T, Song H, Deng H, Xiao B, Xia T, Yu X, Le Y, Guo J. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. *Cancer* 2013; **119**: 1618-1626 [PMID: 23335180 DOI: 10.1002/cncr.27903]

200 **Komatsu S**, Ichikawa D, Tsujiura M, Konishi H, Takeshita H, Nagata H, Kawaguchi T, Hirajima S, Arita T, Shiozaki A, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. *Anticancer Res* 2013; **33**: 271-276 [PMID: 23267156]

201 **Chen Z**, Saad R, Jia P, Peng D, Zhu S, Washington MK, Zhao Z, Xu Z, El-Rifai W. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. *Cancer* 2013; **119**: 1985-1993 [PMID: 23456798 DOI: 10.1002/cncr.28002]

202 **Wang H**, Wang L, Wu Z, Sun R, Jin H, Ma J, Liu L, Ling R, Yi J, Wang L, Bian J, Chen J, Li N, Yuan S, Yun J. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. *Med Oncol* 2014; **31**: 298 [PMID: 25367852 DOI: 10.1007/s12032-014-0298-8]

203 **Fu Z**, Qian F, Yang X, Jiang H, Chen Y, Liu S. Circulating miR-222 in plasma and its potential diagnostic and prognostic value in gastric cancer. *Med Oncol* 2014; **31**: 164 [PMID: 25129310 DOI: 10.1007/s12032-014-0164-8]

204 **Su ZX**, Zhao J, Rong ZH, Wu YG, Geng WM, Qin CK. Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer. *Tumour Biol* 2014; **35**: 12119-12125 [PMID: 25416437 DOI: 10.1007/s13277-014-2516-6]

205 **Marino AL**, Evangelista AF, Vieira RA, Macedo T, Kerr LM, Abrahão-Machado LF, Longatto-Filho A, Silveira HC, Marques MM. MicroRNA expression as risk biomarker of breast cancer metastasis: a pilot retrospective case-cohort study. *BMC Cancer* 2014; **14**: 739 [PMID: 25277099 DOI: 10.1186/1471-2407-14-739]

206 **De Ruyck K**, Duprez F, Ferdinande L, Mbah C, Rios-Velazquez E, Hoebers F, Praet M, Deron P, Bonte K, Speel EJ, Libbrecht L, De Neve W, Lambin P, Thierens H. A let-7 microRNA polymorphism in the KRAS 3'-UTR is prognostic in oropharyngeal cancer. *Cancer Epidemiol* 2014; **38**: 591-598 [PMID: 25127693 DOI: 10.1016/j.canep.2014.07.008]

207 **Zhao B**, Han H, Chen J, Zhang Z, Li S, Fang F, Zheng Q, Ma Y, Zhang J, Wu N, Yang Y. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. *Cancer Lett* 2014; **342**: 43-51 [PMID: 23981581 DOI: 10.1016/j.canlet.2013.08.030]

208 **Zhang J**, Song Y, Zhang C, Zhi X, Fu H, Ma Y, Chen Y, Pan F, Wang K, Ni J, Jin W, He X, Su H, Cui D. Circulating MiR-16-5p and MiR-19b-3p as Two Novel Potential Biomarkers to Indicate Progression of Gastric Cancer. *Theranostics* 2015; **5**: 733-745 [PMID: 25897338 DOI: 10.7150/thno.10305]

209 **Wu J**, Li G, Yao Y, Wang Z, Sun W, Wang J. MicroRNA-421 is a new potential diagnosis biomarker with higher sensitivity and specificity than carcinoembryonic antigen and cancer antigen 125 in gastric cancer. *Biomarkers* 2015; **20**: 58-63 [PMID: 25510566 DOI: 10.3109/1354750X.2014.992812]

210 **Farooqi AA**, Qureshi MZ, Coskunpinar E, Naqvi SK, Yaylim I, Ismail M. MiR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis. *Asian Pac J Cancer Prev* 2014; **15**: 1909-1912 [PMID: 24716910]

211 **Yu X**, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao X, Zhang X, Cui L, Ye G, Le Y, Guo J. Gastric juice miR-129 as a potential biomarker for screening gastric cancer. *Med Oncol* 2013; **30**: 365 [PMID: 23307240 DOI: 10.1007/s12032-012-0365-y]

212 **Bandres E**, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. *Clin Cancer Res* 2009; **15**: 2281-2290 [PMID: 19318487 DOI: 10.1158/1078-0432.CCR-08-1818]

213 **Blanco-Calvo M**, Tarrío N, Reboredo M, Haz-Conde M, García J, Quindós M, Figueroa A, Antón-Aparicio L, Calvo L, Valladares-Ayerbes M. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer. *Future Oncol* 2014; **10**: 1187-1202 [PMID: 24947260 DOI: 10.2217/fon.13.263]

214 **Penna E**, Orso F, Taverna D. miR-214 as a key hub that controls cancer networks: small player, multiple functions. *J Invest Dermatol* 2015; **135**: 960-969 [PMID: 25501033 DOI: 10.1038/jid.2014.479]

215 **Han TS**, Hur K, Xu G, Choi B, Okugawa Y, Toiyama Y, Oshima H, Oshima M, Lee HJ, Kim VN, Chang AN, Goel A, Yang HK. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. *Gut* 2015; **64**: 203-214 [PMID: 24870620 DOI: 10.1136/gutjnl-2013-306640]

216 **Zhang R**, Wang W, Li F, Zhang H, Liu J. MicroRNA-106b~25 expressions in tumor tissues and plasma of patients with gastric cancers. *Med Oncol* 2014; **31**: 243 [PMID: 25218271 DOI: 10.1007/s12032-014-0243-x]

217 **Hu Y**, Wang J, Qian J, Kong X, Tang J, Wang Y, Chen H, Hong J, Zou W, Chen Y, Xu J, Fang JY. Long noncoding RNA GAPLINC regulates CD44-dependent cell invasiveness and associates with poor prognosis of gastric cancer. *Cancer Res* 2014; **74**: 6890-6902 [PMID: 25277524 DOI: 10.1158/0008-5472.CAN-14-0686]

218 **Kang HS**, Kim J, Jang SG, Kwon SY, Park YS, Green JE, Kim HK, Ro J. MicroRNA signature for HER2-positive breast and gastric cancer. *Anticancer Res* 2014; **34**: 3807-3810 [PMID: 24982406]

219 **Yan W**, Wang S, Sun Z, Lin Y, Sun S, Chen J, Chen W. Identification of microRNAs as potential biomarker for gastric cancer by system biological analysis. *Biomed Res Int* 2014; **2014**: 901428 [PMID: 24982912 DOI: 10.1155/2014/901428]

220 **Xu Q**, Dong Q, He C, Liu W, Sun L, Liu J, Xing C, Li X, Wang B, Yuan Y. A new polymorphism biomarker rs629367 associated with increased risk and poor survival of gastric cancer in chinese by up-regulated miRNA-let-7a expression. *PLoS One* 2014; **9**: e95249 [PMID: 24760009 DOI: 10.1371/journal.pone.0095249]

221 **Yang C**, Tang R, Ma X, Wang Y, Luo D, Xu Z, Zhu Y, Yang L. Tag SNPs in long non-coding RNA H19 contribute to susceptibility to gastric cancer in the Chinese Han population. *Oncotarget* 2015; **6**: 15311-15320 [PMID: 25944697]

222 **Gong J**, Liu W, Zhang J, Miao X, Guo AY. lncRNASNP: a database of SNPs in lncRNAs and their potential functions in human and mouse. *Nucleic Acids Res* 2015; **43**: D181-D186 [PMID: 25332392 DOI: 10.1093/nar/gku1000]

223 **Zuo QF**, Zhang R, Li BS, Zhao YL, Zhuang Y, Yu T, Gong L, Li S, Xiao B, Zou QM. MicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZ. *Cell Death Dis* 2015; **6**: e1623 [PMID: 25633292 DOI: 10.1038/cddis.2014.573]

224 **Carvalho J**, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE, Diosdado B, Grabsch H, Santos MA, Meijer G, Seruca R, Carvalho B, Oliveira C. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. *J Pathol* 2012; **228**: 31-44 [PMID: 22450781 DOI: 10.1002/path.4032]

225 **Liang J**, Liu X, Xue H, Qiu B, Wei B, Sun K. MicroRNA-103a inhibits gastric cancer cell proliferation, migration and invasion by targeting c-Myb. *Cell Prolif* 2015; **48**: 78-85 [PMID: 25530421 DOI: 10.1111/cpr.12159]

226 **Xu Y**, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z, Xu H. MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. *Oncogene* 2012; **31**: 1398-1407 [PMID: 21822301 DOI: 10.1038/onc.2011.340]

227 **Yang Q**, Jie Z, Cao H, Greenlee AR, Yang C, Zou F, Jiang Y. Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C. *Carcinogenesis* 2011; **32**: 713-722 [PMID: 21349817 DOI: 10.1093/carcin/bgr035]

228 **Shen J**, Xiao Z, Wu WK, Wang MH, To KF, Chen Y, Yang W, Li MS, Shin VY, Tong JH, Kang W, Zhang L, Li M, Wang L, Lu L, Chan RL, Wong SH, Yu J, Chan MT, Chan FK, Sung JJ, Cheng AS, Cho CH. Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. *Cancer Res* 2015; **75**: 754-765 [PMID: 25503559 DOI: 10.1158/0008-5472.CAN-14-1301]

229 **Zhou X**, Wang Y, Shan B, Han J, Zhu H, Lv Y, Fan X, Sang M, Liu XD, Liu W. The downregulation of miR-200c/141 promotes ZEB1/2 expression and gastric cancer progression. *Med Oncol* 2015; **32**: 428 [PMID: 25502084 DOI: 10.1007/s12032-014-0428-3]

230 **Tang H**, Deng M, Tang Y, Xie X, Guo J, Kong Y, Ye F, Su Q, Xie X. miR-200b and miR-200c as prognostic factors and mediators of gastric cancer cell progression. *Clin Cancer Res* 2013; **19**: 5602-5612 [PMID: 23995857 DOI: 10.1158/1078-0432.CCR-13-1326]

231 **Shinozaki A**, Sakatani T, Ushiku T, Hino R, Isogai M, Ishikawa S, Uozaki H, Takada K, Fukayama M. Downregulation of microRNA-200 in EBV-associated gastric carcinoma. *Cancer Res* 2010; **70**: 4719-4727 [PMID: 20484038 DOI: 10.1158/0008-5472.CAN-09-4620]

232 **Zhang B**, Yin Y, Hu Y, Zhang J, Bian Z, Song M, Hua D, Huang Z. MicroRNA-204-5p inhibits gastric cancer cell proliferation by downregulating USP47 and RAB22A. *Med Oncol* 2015; **32**: 331 [PMID: 25429829 DOI: 10.1007/s12032-014-0331-y]

233 **Bin Z**, Dedong H, Xiangjie F, Hongwei X, Qinghui Y. The microRNA-367 inhibits the invasion and metastasis of gastric cancer by directly repressing Rab23. *Genet Test Mol Biomarkers* 2015; **19**: 69-74 [PMID: 25489984 DOI: 10.1089/gtmb.2014.0210]

234 **Ishimoto T**, Sugihara H, Watanabe M, Sawayama H, Iwatsuki M, Baba Y, Okabe H, Hidaka K, Yokoyama N, Miyake K, Yoshikawa M, Nagano O, Komohara Y, Takeya M, Saya H, Baba H. Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. *Carcinogenesis* 2014; **35**: 1003-1011 [PMID: 24318997 DOI: 10.1093/carcin/bgt402]

235 **Li Z**, Cao Y, Jie Z, Liu Y, Li Y, Li J, Zhu G, Liu Z, Tu Y, Peng G, Lee DW, Park SS. miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. *Cancer Lett* 2012; **323**: 41-47 [PMID: 22469786 DOI: 10.1016/j.canlet.2012.03.029]

236 **Guo L**, Bai H, Zou D, Hong T, Liu J, Huang J, He P, Zhou Q, He J. The role of microRNA-133b and its target gene FSCN1 in gastric cancer. *J Exp Clin Cancer Res* 2014; **33**: 99 [PMID: 25433493 DOI: 10.1186/s13046-014-0099-0]

237 **Feng R**, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. *Cancer Lett* 2010; **298**: 50-63 [PMID: 20619534 DOI: 10.1016/j.canlet.2010.06.004]

238 **Li W**, Jin X, Deng X, Zhang G, Zhang B, Ma L. The putative tumor suppressor microRNA-497 modulates gastric cancer cell proliferation and invasion by repressing eIF4E. *Biochem Biophys Res Commun* 2014; **449**: 235-240 [PMID: 24845562 DOI: 10.1016/j.bbrc.2014.05.011]

239 **Matsuo M**, Nakada C, Tsukamoto Y, Noguchi T, Uchida T, Hijiya N, Matsuura K, Moriyama M. MiR-29c is downregulated in gastric carcinomas and regulates cell proliferation by targeting RCC2. *Mol Cancer* 2013; **12**: 15 [PMID: 23442884 DOI: 10.1186/1476-4598-12-15]

240 **Mu YP**, Tang S, Sun WJ, Gao WM, Wang M, Su XL. Association of miR-193b down-regulation and miR-196a up-regulation with clinicopathological features and prognosis in gastric cancer. *Asian Pac J Cancer Prev* 2014; **15**: 8893-8900 [PMID: 25374225]

241 **Zhou X**, Xu G, Yin C, Jin W, Zhang G. Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK. *Oncotarget* 2014; **5**: 11631-11640 [PMID: 25373785]

242 **Kiga K**, Mimuro H, Suzuki M, Shinozaki-Ushiku A, Kobayashi T, Sanada T, Kim M, Ogawa M, Iwasaki YW, Kayo H, Fukuda-Yuzawa Y, Yashiro M, Fukayama M, Fukao T, Sasakawa C. Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. *Nat Commun* 2014; **5**: 4497 [PMID: 25187177 DOI: 10.1038/ncomms5497]

243 **Wang AM**, Huang TT, Hsu KW, Huang KH, Fang WL, Yang MH, Lo SS, Chi CW, Lin JJ, Yeh TS. Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis. *Oncotarget* 2014; **5**: 5002-5016 [PMID: 24970812]

244 **Tsai KW**, Wu CW, Hu LY, Li SC, Liao YL, Lai CH, Kao HW, Fang WL, Huang KH, Chan WC, Lin WC. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. *Int J Cancer* 2011; **129**: 2600-2610 [PMID: 21960261 DOI: 10.1002/ijc.25919]

245 **Duan Y**, Hu L, Liu B, Yu B, Li J, Yan M, Yu Y, Li C, Su L, Zhu Z, Xiang M, Liu B, Yang Q. Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV. *Mol Cancer* 2014; **13**: 127 [PMID: 24886316 DOI: 10.1186/1476-4598-13-127]

246 **Xie L**, Zhang Z, Tan Z, He R, Zeng X, Xie Y, Li S, Tang G, Tang H, He X. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. *Mol Cell Biochem* 2014; **392**: 153-159 [PMID: 24658854]

247 **Iwaya T**, Fukagawa T, Suzuki Y, Takahashi Y, Sawada G, Ishibashi M, Kurashige J, Sudo T, Tanaka F, Shibata K, Endo F, Katagiri H, Ishida K, Kume K, Nishizuka S, Iinuma H, Wakabayashi G, Mori M, Sasako M, Mimori K. Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer. *Clin Cancer Res* 2013; **19**: 6438-6449 [PMID: 24097871 DOI: 10.1158/1078-0432.CCR-12-3186]

248 **Zhang L**, Liu X, Jin H, Guo X, Xia L, Chen Z, Bai M, Liu J, Shang X, Wu K, Pan Y, Fan D. miR-206 inhibits gastric cancer proliferation in part by repressing cyclinD2. *Cancer Lett* 2013; **332**: 94-101 [PMID: 23348698 DOI: 10.1016/j.canlet.2013.01.023]

249 **Sacconi A**, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, Ercolani C, Di Agostino S, Cambria AM, Germoni S, Grasso G, Blandino R, Panebianco V, Ziparo V, Federici O, Muti P, Strano S, Carboni F, Mottolese M, Diodoro M, Pescarmona E, Garofalo A, Blandino G. miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. *Cell Death Dis* 2012; **3**: e423 [PMID: 23152059 DOI: 10.1038/cddis.2012.160]

250 **Li C**, Nie H, Wang M, Su L, Li J, Yu B, Wei M, Ju J, Yu Y, Yan M, Gu Q, Zhu Z, Liu B. MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. *Cancer Lett* 2012; **320**: 189-197 [PMID: 22388101 DOI: 10.1016/j.canlet.2012.02.030]

251 **Zheng B**, Liang L, Huang S, Zha R, Liu L, Jia D, Tian Q, Wang Q, Wang C, Long Z, Zhou Y, Cao X, Du C, Shi Y, He X. MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. *Oncogene* 2012; **31**: 4509-4516 [PMID: 22179828 DOI: 10.1038/onc.2011.581]

252 **Zheng B**, Liang L, Wang C, Huang S, Cao X, Zha R, Liu L, Jia D, Tian Q, Wu J, Ye Y, Wang Q, Long Z, Zhou Y, Du C, He X, Shi Y. MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. *Clin Cancer Res* 2011; **17**: 7574-7583 [PMID: 21994419 DOI: 10.1158/1078-0432.CCR-11-1714]

253 **Song YX**, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, Zhang X, Jiang L, Xing CZ, Zhang Y. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. *Mol Cancer* 2011; **10**: 1 [PMID: 21205300 DOI: 10.1186/1476-4598-10-1]

254 **Bou Kheir T**, Futoma-Kazmierczak E, Jacobsen A, Krogh A, Bardram L, Hother C, Grønbæk K, Federspiel B, Lund AH, Friis-Hansen L. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. *Mol Cancer* 2011; **10**: 29 [PMID: 21418558 DOI: 10.1186/1476-4598-10-29]

255 **Oh HK**, Tan AL, Das K, Ooi CH, Deng NT, Tan IB, Beillard E, Lee J, Ramnarayanan K, Rha SY, Palanisamy N, Voorhoeve PM, Tan P. Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer. *Clin Cancer Res* 2011; **17**: 2657-2667 [PMID: 21415212 DOI: 10.1158/1078-0432.CCR-10-3152]

256 **Zhang X**, Yan Z, Zhang J, Gong L, Li W, Cui J, Liu Y, Gao Z, Li J, Shen L, Lu Y. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. *Ann Oncol* 2011; **22**: 2257-2266 [PMID: 21343377 DOI: 10.1093/annonc/mdq758]

257 **Nishida N**, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. *Clin Cancer Res* 2011; **17**: 2725-2733 [PMID: 21220473 DOI: 10.1158/1078-0432.CCR-10-2132]

258 **Takei Y**, Takigahira M, Mihara K, Tarumi Y, Yanagihara K. The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer. *Cancer Res* 2011; **71**: 1442-1453 [PMID: 21169410 DOI: 10.1158/0008-5472.CAN-10-2530]

259 **Hashimoto Y**, Akiyama Y, Otsubo T, Shimada S, Yuasa Y. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. *Carcinogenesis* 2010; **31**: 777-784 [PMID: 20080834 DOI: 10.1093/carcin/bgq013]

260 **Wada R**, Akiyama Y, Hashimoto Y, Fukamachi H, Yuasa Y. miR-212 is downregulated and suppresses methyl-CpG-binding protein MeCP2 in human gastric cancer. *Int J Cancer* 2010; **127**: 1106-1114 [PMID: 20020497 DOI: 10.1002/ijc.25126]

261 **Huang N**, Wu Z, Lin L, Zhou M, Wang L, Ma H, Xia J, Bin J, Liao Y, Liao W. MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling. *Oncotarget* 2015; **6**: 15222-15234 [PMID: 25945841]

262 **Chen DL**, Zhang DS, Lu YX, Chen LZ, Zeng ZL, He MM, Wang FH, Li YH, Zhang HZ, Pelicano H, Zhang W, Xu RH. microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. *Oncotarget* 2015; **6**: 10868-10879 [PMID: 25869101]

263 **Kang W**, Tong JH, Lung RW, Dong Y, Zhao J, Liang Q, Zhang L, Pan Y, Yang W, Pang JC, Cheng AS, Yu J, To KF. Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. *Mol Cancer* 2015; **14**: 52 [PMID: 25743273 DOI: 10.1186/s12943-015-0323-3]

264 **Ma G**, Dai W, Sang A, Yang X, Gao C. Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer. *Int J Clin Exp Pathol* 2014; **7**: 8833-8840 [PMID: 25674252]

265 **Xu X**, Wang W, Su N, Zhu X, Yao J, Gao W, Hu Z, Sun Y. miR-374a promotes cell proliferation, migration and invasion by targeting SRCIN1 in gastric cancer. *FEBS Lett* 2015; **589**: 407-413 [PMID: 25554419 DOI: 10.1016/j.febslet.2014.12.027]

266 **Wang Z**, Ma X, Cai Q, Wang X, Yu B, Cai Q, liu B, Zhu Z, Li C. MiR-199a-3p promotes gastric cancer progression by targeting ZHX1. *FEBS Lett* 2014; **588**: 4504-4512 [PMID: 25448600 DOI: 10.1016/j.febslet.2014.09.047]

267 **Pan Y**, Ren F, Zhang W, Liu G, Yang D, Hu J, Feng K, Feng Y. Regulation of BGC-823 cell sensitivity to adriamycin via miRNA-135a-5p. *Oncol Rep* 2014; **32**: 2549-2556 [PMID: 25322930 DOI: 10.3892/or.2014.3546]

268 **Zhao X**, He L, Li T, Lu Y, Miao Y, Liang S, Guo H, Bai M, Xie H, Luo G, Zhou L, Shen G, Guo C, Bai F, Sun S, Wu K, Nie Y, Fan D. SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. *Cell Death Differ* 2014; **21**: 1900-1913 [PMID: 25080937 DOI: 10.1038/cdd.2014.109]

269 **Li BS**, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, Wu C, Yang SM, Zeng H, Zou QM, Guo G. MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. *Oncogene* 2015; **34**: 2556-2565 [PMID: 25043310 DOI: 10.1038/onc.2014.214]

270 **Liu J**, Wang X, Yang X, Liu Y, Shi Y, Ren J, Guleng B. miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells. *Cancer Lett* 2014; **347**: 98-104 [PMID: 24486742 DOI: 10.1016/j.canlet.2014.01.024]

271 **Deng Y**, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, Zhang X, Shen M, Yan X, Wang L, Wang X, Kang Y, Si J, Zhou T. MiR-215 modulates gastric cancer cell proliferation by targeting RB1. *Cancer Lett* 2014; **342**: 27-35 [PMID: 23981575 DOI: 10.1016/j.canlet.2013.08.033]

272 **Wu Q**, Yang Z, Wang F, Hu S, Yang L, Shi Y, Fan D. MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. *J Cell Sci* 2013; **126**: 4220-4229 [PMID: 23868977 DOI: 10.1242/jcs.127944]

273 **Li T**, Lu YY, Zhao XD, Guo HQ, Liu CH, Li H, Zhou L, Han YN, Wu KC, Nie YZ, Shi YQ, Fan DM. MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1. *Oncogene* 2014; **33**: 783-793 [PMID: 23353818 DOI: 10.1038/onc.2012.637]

274 **Lin Y**, Nie Y, Zhao J, Chen X, Ye M, Li Y, Du Y, Cao J, Shen B, Li Y. Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility. *Carcinogenesis* 2012; **33**: 2377-2383 [PMID: 22971574 DOI: 10.1093/carcin/bgs292]

275 **Sun M**, Liu XH, Li JH, Yang JS, Zhang EB, Yin DD, Liu ZL, Zhou J, Ding Y, Li SQ, Wang ZX, Cao XF, De W. MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1). *Mol Cancer Ther* 2012; **11**: 842-852 [PMID: 22343731 DOI: 10.1158/1535-7163.MCT-11-1015]

276 **Liao YL**, Hu LY, Tsai KW, Wu CW, Chan WC, Li SC, Lai CH, Ho MR, Fang WL, Huang KH, Lin WC. Transcriptional regulation of miR-196b by ETS2 in gastric cancer cells. *Carcinogenesis* 2012; **33**: 760-769 [PMID: 22298639 DOI: 10.1093/carcin/bgs023]

277 **Liu H**, Zhu L, Liu B, Yang L, Meng X, Zhang W, Ma Y, Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. *Cancer Lett* 2012; **316**: 196-203 [PMID: 22169097 DOI: 10.1016/j.canlet.2011.10.034]

278 **Lo SS**, Hung PS, Chen JH, Tu HF, Fang WL, Chen CY, Chen WT, Gong NR, Wu CW. Overexpression of miR-370 and downregulation of its novel target TGFβ-RII contribute to the progression of gastric carcinoma. *Oncogene* 2012; **31**: 226-237 [PMID: 21666718 DOI: 10.1038/onc.2011.226]

279 **Jin Z**, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y, Olaru AV, Yang J, David S, Hamilton JP, Abraham JM, Harmon J, Duncan M, Montgomery EA, Meltzer SJ. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. *Oncogene* 2011; **30**: 1577-1585 [PMID: 21119604 DOI: 10.1038/onc.2010.534]

280 **Kurashige J**, Mima K, Sawada G, Takahashi Y, Eguchi H, Sugimachi K, Mori M, Yanagihara K, Yashiro M, Hirakawa K, Baba H, Mimori K. Epigenetic modulation and repression of miR-200b by cancer-associated fibroblasts contribute to cancer invasion and peritoneal dissemination in gastric cancer. *Carcinogenesis* 2015; **36**: 133-141 [PMID: 25411357 DOI: 10.1093/carcin/bgu232]

281 **Cao LL**, Xie JW, Lin Y, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY, Huang CM. miR-183 inhibits invasion of gastric cancer by targeting Ezrin. *Int J Clin Exp Pathol* 2014; **7**: 5582-5594 [PMID: 25337200]

282 **Crone SG**, Jacobsen A, Federspiel B, Bardram L, Krogh A, Lund AH, Friis-Hansen L. microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. *Mol Cancer* 2012; **11**: 71 [PMID: 22992343 DOI: 10.1186/1476-4598-11-71]

283 **Yao Q**, Cao Z, Tu C, Zhao Y, Liu H, Zhang S. MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. *Cancer Lett* 2013; **335**: 219-224 [PMID: 23435376 DOI: 10.1016/j.canlet.2013.02.031]

284 **Rotkrua P**, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. *Int J Cancer* 2011; **129**: 2611-2620 [PMID: 21225631 DOI: 10.1002/ijc.25923]

285 **Tsai KW**, Liao YL, Wu CW, Hu LY, Li SC, Chan WC, Ho MR, Lai CH, Kao HW, Fang WL, Huang KH, Lin WC. Aberrant hypermethylation of miR-9 genes in gastric cancer. *Epigenetics* 2011; **6**: 1189-1197 [PMID: 21931274 DOI: 10.4161/epi.6.10.16535]

286 **Wan HY**, Guo LM, Liu T, Liu M, Li X, Tang H. Regulation of the transcription factor NF-kappaB1 by microRNA-9 in human gastric adenocarcinoma. *Mol Cancer* 2010; **9**: 16 [PMID: 20102618 DOI: 10.1186/1476-4598-9-16]

287 **Ding L**, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J, Zhou T. MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. *Cell Res* 2010; **20**: 784-793 [PMID: 20548334 DOI: 10.1038/cr.2010.79]

288 **Tsukamoto Y**, Nakada C, Noguchi T, Tanigawa M, Nguyen LT, Uchida T, Hijiya N, Matsuura K, Fujioka T, Seto M, Moriyama M. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. *Cancer Res* 2010; **70**: 2339-2349 [PMID: 20215506 DOI: 10.1158/0008-5472.CAN-09-2777]

289 **Shi Y**, Chen GB, Huang QW, Chen X, Liu JJ, Xu W, Huang XX, Liu YP, Xiao CX, Wu DC, Guleng B, Ren JL. miR218-5p regulates the proliferation of gastric cancer cells by targeting TFF1 in an Erk1/2-dependent manner. *Biochim Biophys Acta* 2015; **1852**: 970-979 [PMID: 25652124 DOI: 10.1016/j.bbadis.2015.01.016]

290 **Tie J**, Pan Y, Zhao L, Wu K, Liu J, Sun S, Guo X, Wang B, Gang Y, Zhang Y, Li Q, Qiao T, Zhao Q, Nie Y, Fan D. MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. *PLoS Genet* 2010; **6**: e1000879 [PMID: 20300657 DOI: 10.1371/journal.pgen.1000879]

**P-Reviewer:** Kim HH, Wang yh **S-Editor:** Ma YJ **L-Editor:****E-Editor:**

**Table 1 MicroRNAs down-regulated in gastric cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ncRNAs | Summary of findings/clinical relevance | q-PCR | Targets | Roles | Cases | Location | Ref. |
| miR-141 | Reduced in metastasis positive tissues; Might be a prognostic marker and therapeutic target. | √ | TAZ | Proliferation, invasion and  migration | 36 GC *vs* paired adjacent tissues. | China | [223] |
| miR-874 | Reduced miR-874 promotes angiogenesis via STAT3; Might be a therapeutic target. | √ | STAT3 | Tumor growth and angiogenesis | 80 GC *vs* paired adjacent tissues. | China | [187] |
| miR-101 | Lower level parallels with EZH2 over-expression. | √ | EZH2 | E-cadherin  dysfunction | 37 GC *vs* 5 normal gastric mucosa. | Portugal | [224] |
| miR-103a | Tumor suppressor by targeting c-Myb. | √ | c-Myb | Proliferation,  invasion and migration | 80 GC *vs* paired adjacent tissues. | China | [225] |
| miR-335 | Can be silenced by promoter hypermethylation which might be a predictive epigenetic marker and a therapeutic strategy. | √ | RASA1 | Invasion and metastasis | 15 GC *vs* paired adjacent tissues. | China | [52] |
| miR-335 | Could be a therapeutic target for GC therapies and a prognostic factor. | √ | Bcl-w,  SP1 | Proliferation,  invasion and metastasis | 70 GC *vs* paired adjacent tissues. | China | [226] |
| let-7a | A potential target for diagnosis and therapy. | √ | RAB40C | Proliferation and colony formation | 27 GC *vs* paired adjacent tissues. | China | [227] |
| miR-490-3p | Reduced miR-490-3p reactivates SMARCD1 to confer malignant phenotypes. | √ | SMARCD1 | Growth and metastasis | 14 GC *vs* 15 normal gastric tissues. | Hong Kong | [228] |
| miR-200c/141 | Reduced the miRNAs decreases ZEB1/2 expression and increased E-cadherin expression.. | √ | ZEB1/2 | Invasion and migration | 64 GC *vs* paired adjacent tissues. | China | [229] |
| miR-200b /c | Might be markers of prognosis and therapeutic targets. | √ | DNMT3A,DNMT3B,SP1 | Proliferation, invasion and migration | 36 GC *vs* paired adjacent tissues. | China | [230] |
| miR-200 | Downregulated miR-200 reduced E-cadherin expression plying a rolein the carcinogenesis of EBV-associated GC. | √ | ZEB1,  ZEB2 | Cell-to-cell adhesion  and migration. | 36 GC *vs* paired adjacent tissues (EBV-associated and EBV-negative). | Japan | [231] |
| miR-204-5p | Restoration of miR-204-5p might provide a therapeutic strategy for GC. | √ | USP47,  RAB22A | Proliferation | 102 GC *vs* paired adjacent tissues. | China | [232] |
| miR-367 | A key negative regulator of invasion and metastasis of GC; Might be a therapeutic target. | √ | Rab23 | Invasion and migration | 37 GC *vs* paired adjacent tissues. | China | [233] |
| miR-328 | MiR-328-mediated CD44 overexpression may associate with the carcinogenesis of GC. | √ | CD44v9 | Survival and proliferation of metaplastic cells | 54 patients underwent gastric resection without preoperative treatment. | Japan | [181] |
| miR-328 | Macrophages mediated miR-328-CD44 signaling may be a therapeutic target for gastrointestinal cancer. | √ | CD44 | Cell growth and drug resistance | 63 GC *vs* paired adjacent tissues. | Japan | [234] |
| miR-495 | A tumor suppressor and potential therapeutic target for GC peritoneal metastasis. | √ | PRL-3 | Invasion and metastasis | 20 GC *vs* 10 normal gastric tissues. | China | [53] |
| miR-551a | A tumor suppressor targeting PRL-3 oncogene to inhibit GC cell migration and invasion. | √ | PRL-3 | Invasion and migration | 30 malignant *vs* 4 normal gastric tissues. | China | [235] |
| miR-133b | A potential diagnostic marker and therapeutic target. | √ | FSCN1 | Proliferation, invasion and migration | 100 GC *vs* paired adjacent tissues. | China | [236] |
| miR-542-3p | A Tumor suppressor and a potential therapeutic target. | √ | AEG-1 | Cell growth | 22 GC *vs* paired adjacent tissues. | China | [112] |
| miR-126 | Suppress tumor growth and angiogenesis of through targeting VEGF-A; A potential therapeutic target. | √ | VEGF-A | Tumori-  genicity and angiogenesis | 68 GC *vs* paired adjacent tissues. | China | [119] |
| miR-126 | miR-126 may function as a tumor suppressor in GC. | √ | Crk | Proliferation, cell cycle, apoptosis, invasion and migration | 60 GC *vs* paired adjacent tissues. | China | [237] |
| miR-29s | Increasing the expression of miR-29s may be a therapeutic strategy for GC. | √ | AKT2 | Invasion | 20 GC *vs* paired adjacent tissues. | China | [120] |
| miR-29c | Reduced miR-29c expression is an early event in GC development; Potential diagnostic and therapeutic biomarkers. | √ | ITGB1 | Proliferation, adhesion, invasion and migration | 274 GC *vs* paired adjacent tissues. | South Korea,  Japan,  United States | [215] |
| miR-29 family | Might be potential prognostic markers and therapeutic targets. | √ | CCND2,  MMP-2 | Proliferation apoptosis and invasion | 115 GC *vs* paired adjacent tissues. | China | [238] |
| miR-29c | Might be a tumor suppressor. | √ | RCC2 | Proliferation and colony formation | 12 GC *vs* paired adjacent tissues. | Japan | [239] |
| miR-193b | Might be a potential prognostic marker. | √ | Unknown | Differentia-  tion and survival | 48 GC *vs* paired adjacent tissues. | China | [240] |
| miR-203 | Might be a therapeutic target for *H. pylori* infection induced GC. | √ | CASK | Proliferation and invasion | 50 pairs of *H. pylori* positive and negative gastric tissues. | China | [241] |
| miR-210 | Epigenetic silencing of miR-210 involves in chronic *H. pylori* infection associated GC. | √ | STMN1,  DIMT1 | Proliferation | 20 GC *vs* paired adjacent tissues. | Japan | [242] |
| miR-34 family | Plays an role in the control of GC development. | √ | Yin Yang 1 | Growth, colony formation, migration, invasion, and tumorsphere formation | 32 GC *vs* paired adjacent tissues. | Taiwan | [243] |
| miR-34b and  miR-129-3p | Downregulated by hypermethylation of upstream CpG islands indicating a poor clinical outcome. | √ | Unknown | Unknown | 72 GC *vs* paired adjacent tissues. | Taiwan | [244] |
| miR-24 | A novel tumor suppressor and a potential therapeutic target. | √ | RegIV | Proliferation, invasion and migration | 63 GC *vs* paired adjacent tissues. | China | [245] |
| miR-185 | Regulating the sensitivity of GC to chemotherapy. | √ | ARC | Chemotherapeutic sensitivity | 25 GC *vs* paired adjacent tissues. | China | [246] |
| miR-1207-5p and miR-1266 | hTERT suppressors in GC and potential therapeutic targets.. | √ | hTERT | Cell growth, cell cycle and invasion | 58 GC *vs* adjacent tissues. | China | [108] |
| miR-365 | Playing a role in tumorigenesis; A potential therapeutic target. | √ | Cyclin D1,  cdc25A | Proliferation and colony formation | 127 GC *vs* paired adjacent tissues. | China | [105] |
| miR-760 | A potential prognostic predictor and therapeutic target. | √ | Histone mRNA | Unknown | 53 bone marrow samples from stage IV patients *vs* 52 stage I patients; 22 stage IV GC *vs* 29 stage I GS tissues. | Japan | [247] |
| miR-143/145 | DDX6 contributes to the control of NCR143/145 RNA stability in P-bodies and post-transcriptionally regulated miR-143/145 expression. | √ | Unknown | Cell survival, proliferation  and malignant transforma-  tion | 14 GC tissues *vs* paired adjacent tissues. | Japan | [84] |
| miR-206 | A potential tumor suppressor and therapeutic target. | √ | CyclinD2 | Proliferation,  cell cycle and  tumor growth | 30 primary GC *vs* paired distant tissues. | China | [248] |
| miR-204 | A potential target for preventive and therapeutic strategies. | √ | Bcl-2 | Migration, colony forming and chemotherapy resistance | 92 gastric tumor specimens *vs* paired adjacent tissues. | Italy | [249] |
| miR-124 | A tumor suppressor; Play a role in miRNA-mediated SPHK1 expression. | √ | SPHK1 | Proliferation and tumouri-  genicity | 20 GC *vs* paired adjacent tissues. | China | [117] |
| miR-409-3p | A tumor suppressor involving the direct targeting and inhibition of PHF10. | √ | PHF10. | Proliferation and apoptosis | 67 GC *vs* paired adjacent tissues. | China | [250] |
| miR-409-3p | Suppresses GC invasion and metastasis by directly targeting RDX; Reduced miR-409-3p is prone to lymph node metastasis. | √ | RDX | Invasion and migration | 90 GC *vs* paired adjacent tissues. | China | [251] |
| miR-148a | Reduced miR-148a contributes to GC lymph node-metastasis and progression; A potential therapeutic target for GC metastasis. | √ | ROCK1 | Invasion, migration and metastasis | 90 GC *vs* paired normal tissues. | China | [252] |
| miR-148b | A potential biomarker and therapeutic target. | √ | CCKBR | Proliferation and tumori-  genicity | 106 GC *vs* paired adjacent tissues. | China | [253] |
| miR-449 | A member of the miR-34 family playing an important role in GC. | √ | GMNN,  MET,  CCNE2,  SIRT1 | Cell cycle, proliferationand induce senescence | 10 GC *vs* paired adjacent tissues. | Denmark | [254] |
| miR-486 | A tumor-suppressor. Associated with the direct targeting and inhibition of OLFM4. | √ | OLFM4 | Proliferation, invasion and migration | 29 GC *vs* paired adjacent tissues. | Singapore | [255] |
| miR-142-5p | A potential predictor of progression and predict recurrence risk for GC. | √ | MAPK, Wnt,  VEGF | Recurrence  risk related | 65 GC samples. | China | [256] |
| miR-125a-5p | Reduced miR-125a-5p is associated with enhanced malignant potential; A potential prognostic marker. | √ | ERBB2 | Proliferation | 87 GC samples. | Japan | [257] |
| miR-516a-3p | An anti-metastamir with therapeutic potential in blocking metastatic dissemination of GC. | √ | SULF1 | Proliferation, invasion and migration | 8 normal stomach tissues, 12 GC tissues from the patients with peritoneal dissemination and 12 GC tissues without peritoneal dissemination. | Japan | [258] |
| miR-181c | Silenced through methylation playing important roles in gastric carcinogenesis. | √ | NOTCH4, and KRAS | Proliferation | 16 GC surgical specimens *vs* paired non-cancerous counterparts. | Japan | [259] |
| miR-212 | Reduced miR-212 may be related to gastric carcinogenesis. | √ | MECP2 | Proliferation | 11 GC *vs* paired adjacent tissues. | Japan | [260] |
| miR-338-3p | MiR-338-3p inhibits the EMT progression in GC cells by targeting ZEB2 and MACC1/Met/Akt pathway. | √ | ZEB2, MACC1 | Invasionand migration | 20 GC *vs* paired adjacent tissues. | China | [261] |
| miR-217 | A potential prognostic marker; miR-217-EZH2 axis may be a potential therapeutic target. | √ | EZH2 | Proliferation, invasionand migration | 83 GC tissues *vs* adjacent tissues. | China,  United States | [262] |
| miR-15a and miR-16-1 | MiR-15a and miR-16-1 play inhibitory effect providing a therapeutic potential in GC. | √ | YAP1 | Proliferation, colony formation, invasion and migration | 60 GC *vs* paired adjacent tissues. | Hong Kong | [263] |

GC: gastric cancer.

**Table 2 MicroRNAs up-regulated in gastric cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ncRNAs | Summary of findings/clinical relevance | q-PCR | Targets | Roles | Cases | Location | Ref. |
| miR-23a/b | Implicated in the progression of GC. A potential prognosis marker. | √ | Unknown | Unknown | 160 GC *vs* adjacent tissues. | China | [264] |
| miR-500 | Highly correlated with malignant progression and poor survival of GC. | √ | CYLD, TAX1BP1, OTUD7B | Proliferation, survival and tumori-  genicity | 10 GC *vs* adjacent tissues. | China | [137] |
| miR-374a | A promising therapeutic target. | √ | SRCIN1 | Proliferation,  tumor growth migration  and invasion | 18 GC tissues *vs* adjacent tissues. | China | [265] |
| miR-199a-3p | A tumor promoter in GC targeting and inhibition of ZHX1; A potential target for GC prevention and therapy. | √ | ZHX1 | Proliferation  and apoptosis | 52 GC *vs* adjacent tissues. | China | [266] |
| miR-18a | A potential marker for risk stratification in the management of GC patient. | √ | PIAS3,  [STAT3](http://link.springer.com/search?dc.title=STAT3&facet-content-type=ReferenceWorkEntry&sortOrder=relevance) | Unknown | 82 patients with GC and 65 healthy controls. (plasma) | China | [204] |
| miR-196a | A potential prognostic marker in GC. | √ | Unknown | Differentiation andsurvival | 48 GC *vs* adjacent tissues. | China | [240] |
| miR-223,  miR-16,  miR-100 | Up-regulated in serum implicates their potential diagnostic value;. Significantly elevated expression of the three miRNAs in advanced GC patients suggests their availability in cancer staging. | √ | PIAS3 | Unknown | 50 GC patients and 47 healthy controls.(serum) | China | [202] |
| miR‑135a-5p | Play a role in miRNA-135a-5p-AP-2α-BCL-2 pathway providing therapeutic potential for GC and solution for insensitivity of GC to chemotherapy. | √ | AP-2α | Cell resistance to apoptosis, sensitivity to adriamycin | 20 GC *vs* adjacent tissues. | China | [267] |
| miR-199a-5p | SRF/miR-199a-5p/E-cadherin pathway promotes GC EMT and metastasis; A potential therapeutic target or biomarker for GC progression. | √ | E-cadherin | Adhesion, invasion, and metastasis | 7 GC *vs* pairs adjacent tissues. | China | [268] |
| miR-25 | A potential biomarker for the prognosis of GC. | √ | ERBB2, 1(TOB1) | Migration, invasion and proliferation | 33 GC *vs* paired adjacent tissues. | China | [269] |
| miR-942 | A potential drug response biomarker and therapeutic target for TRAIL resistant tumors. | √ | ISG12a | Apoptosis | 28 GC tissues. | China | [134] |
| miR-196a/b | A potential Therapeutic target in suppressing GC metastasis. | √ | Radixin | Metastasis | 109 GC *vs* paired adjacent tissues. | Taiwan | [172] |
| miR-19a/b | A member of miR-19a/b facilitating GC cell migration, invasion and metastasis, implicating a novel mechanism for the malignant phenotypes of GC. | √ | MXD1 | Migration and invasion | 141 GC *vs* paired adjacent tissues. | China | [173] |
| miR-423-5p | A potential therapeutic target. | √ | TFF1 | Proliferation and invasion | 15 GC *vs* paired adjacent tissues. | China | [270] |
| miR-183-96-182 cluster | A novel role for GSK3β in the regulation of miR-183-96-182 biogenesis through β-Catenin/TCF/ LEF-1 pathway in GC. | √ | FoxO1 | Proliferation and migration | 8 GC *vs* paired adjacent tissues. | United States | [83] |
| miR-215 | Influencing cell proliferation by targeting RB1. | √ | RB1 | Proliferation | 51 GC *vs* paired adjacent tissues. | China | [271] |
| miR-17-92 cluster | Cluster including miR-19b, miR-20a and miR-92a associates with the development of GC stem cells; and miR-92a has the A potential predictive prognostic marker for miR-92a in GC. | √ | E2F1, HIPK1 | Self-renewal and proliferation | 97 GC specimens. | China | [272] |
| miR-296-5p | MiR-296-5p-CDX1-ERK1/2 axis play a role in gastric tumorigenesis; A potential therapeutic target. | √ | CDX1 | Proliferation | 16 GC *vs* paired adjacent tissues. | China | [273] |
| miR-181a | Associated with increased risk and poor survival of GC. | √ | MTMR3 | Unknown | 50 GC *vs* paired adjacent tissues. | China | [274] |
| miR-196a | Contributing to gastric carcinogenesis; A potential therapeutic target and prognostic factor. | √ | p27 | Proliferation, apoptosis and tumorigenesis | 36 GC *vs* paired adjacent tissues. | China | [275] |
| miR-196b | Transcriptionally regulated by ETS2; A potential diagnostic marker and therapeutic target. | √ | AnnexinA1, HOXB8 | Migration and invasion | 63 GC *vs* paired adjacent tissues. | Taiwan | [276] |
| miR-378 | Up-regulated in serum while down-regulated in GC tissues. A potential serum biomarker in GC detection. | √ | Unknown | Unknown | 4 GC *vs* paired adjacent tissues, 40 GC serum samples *vs* 41 healthy controls. | China | [277] |
| miR-370 | Associated with GC progression by targeting TGFβ-RII. | √ | TGFβ-RII | Migration | 33 GC *vs* adjacent tissues. | Taiwan | [278] |
| miR-192  miR-215 | Exerting cell growth and migration-promoting effects. | √ | ALCAM | Migration, invasion, proliferation, cell cycle and apoptosis | 31 non-neoplastic stomach tissues and 25 GC tissues. | United States | [279] |
| miR-200b | A potential diagnostic and prognostic biomarker; A potential therapeutic target for peritoneal dissemination. | √ | Unknown | Migration and invasion | 173GC *vs* paried normal gastric epithelium tissues. | Japan | [280] |

GC: gastric cancer.

**Table 3 MicroRNAs up-regulated or down-regulated in gastric cancer**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| ncRNAs | Summary of findings/Clinical relevance | q-PCR | Targets | Roles | Cases | Location | Ref. |
| miR-183 ↑ | A potential biomarker for GC progression and therapeutic target. | √ | PDCD4 | Proliferation, migration, invasion, and apoptosis | 80 GC *vs* 20 non-tumorous gastric mucosa tissues. | China | [131] |
| miR-183 ↓ | A tumor suppressor partially through regulation of Ezrin; A potential therapeutic target. | √ | Ezrin | Invasion | 52 pairs of paraffin-embedded GC and adjacent tissues; 5 fresh tissues samples from three patients. | China | [281] |
| miR-146a ↑ | A key factor in the regulation of NF-κB activity. | √ | CARD10, COPS8 | Inhibits NF-κB activation | 37 GC *vs* paired adjacent tissues. | Denmark | [282] |
| miR-146a/b ↓ | MiR-146a/b/UHRF1 axis associates with the GC metastasis; A potential therapeutic target in blocking GC metastasis. | √ | UHRF1 | Invasion and metastasis | 15 primary GC tissues compared with matched adjacent normal tissues. | China | [180] |
| miR-146a ↓ | MiR-146a/WASF2 axis may associate the migration and invasion of GC cells; A potential therapeutic target. | √ | WASF2 | Invasion and metastasis | 20 GC *vs* paired adjacent tissues. | China | [283] |
| miR-146a ↓ | Targeting EGFR and IRAK1; A potential prognostic factor. | √ | EGFR, IRAK1 | Invasion and metastasis | 90 GC *vs* paired adjacent tissues. | Japan | [179] |
| miR-9 ↑ | Targeting and suppressing CDX2 expression promote GC cell proliferation . | √ | CDX2 | Proliferation | 27 GC tissues. | Japan | [284] |
| miR-9 ↓ | Ectopic expression of miR-9 inhibits the proliferation, migration and invasion of GC cells. | √ | MMP2, MMP9, Twist,  N-cad-  herin | Invasion and metastasis | 72 GC *vs* adjacent tissues. | Taiwan | [285] |
| miR-9 ↓ | A tumor suppressor targeting NF-kappaB1. | √ | NF-κB1 | Proliferation | 9 GC *vs* paired adjacent tissues. | China | [286] |
| miR-375 ↑ | A predictor of GC; progression and recurrence risk for GC patients. | √ | P53, MAPK, Wnt, VEGF | High frequency recurrence and poor survival | 34 frozen fresh tissues and 38 paraffin-embedded tissues. | China | [256] |
| miR-375 ↓ | A tumor suppressor; Playing a role in gastric tumorigenesis. | √ | JAK2 | Proliferation | 48 GC *vs* paired adjacent tissues. | China | [287] |
| miR-375 ↓ | A tumor suppressor. | √ | PDK1,  14-3-3zeta | Apoptosis, proliferation | 22 samples from GC and 5 normal control tissues. | Japan | [288] |
| miR-218-5p ↑ | MiR-218-5p targets and suppresses TFF1 and influences the progression of GC in an Erk1/2-dependent manner; A potential therapeutic target. | √ | TFF1 | Proliferation | 42 GC *vs* paired adjacent tissues. | China | [289] |
| miR-218 ↓ | Disruption of Slit-miR-218-Robo1 regulatory circuit may contribute to GC metastasis. A potential therapeutic target in blocking GC metastasis. | √ | Robo1 | Invasion and metastasis | 40 GC *vs* paired adjacent tissues. | China | [290] |

GC: gastric cancer.